Gadsden Properties (GADS) 10-Q 11 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Aug. 11, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'PHOTOMEDEX INC	'
Entity Central Index Key	'0000711665	'
Current Fiscal Year End Date	'--12-31	'
Entity Well-known Seasoned Issuer	'No	'
Entity Voluntary Filers	'No	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	19,049,582
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$36,662	$45,388
Short term bank deposit	0	14,113
Accounts receivable, net of allowance for doubtful accounts of $12,020 and $10,734, respectively	21,374	27,218
Inventories, net	25,618	27,547
Deferred tax asset	14,085	13,041
Prepaid expenses and other current assets	15,296	12,597
Total current assets	113,035	139,904
Property and equipment, net	29,138	10,489
Patents and licensed technologies, net	9,960	10,832
Other intangible assets, net	48,085	9,701
Goodwill	75,010	24,930
Deferred tax asset	24,008	24,039
Other assets	3,322	213
Total assets	302,558	220,108
Current liabilities:	'	'
Current portion of notes payable	416	838
Current portion of debt	85,185	10,000
Accounts payable	17,461	14,785
Accrued compensation and related expenses	3,974	3,230
Other accrued liabilities	15,967	22,032
Deferred revenues	5,460	5,961
Total current liabilities	128,463	56,846
Long-term liabilities:	'	'
Long-term note payable, net of current maturities	53	82
Long-term debt, net of current portion	681	0
Deferred revenues	2,031	2,758
Deferred tax liability	8,909	0
Other liabilities	7,279	61
Total liabilities	147,416	59,747
Commitments and Contingencies (Note 12)	'	'
Stockholders' equity:	'	'
Preferred Stock, $.01 par value, 5,000,000 shares authorized; 0 shares issued and outstanding at June 30, 2014 and December 31, 2013	0	0
Common stock, $.01 par value, 50,000,000 shares authorized; 19,049,582 and 18,903,245 shares issued and outstanding at June 30, 2014 and December 31, 2013, respectively	190	189
Additional paid-in capital	106,529	104,954
Retained earnings	45,854	53,679
Accumulated other comprehensive income	2,569	1,539
Total stockholders' equity	155,142	160,361
Total liabilities and stockholders' equity	$302,558	$220,108

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Current assets:	'	'
Accounts receivable, allowance for doubtful accounts	$12,020	$10,734
Stockholders' Equity	'	'
Preferred Stock, par value (in dollars per share)	$0.01	$0.01
Preferred Stock, authorized (in shares)	5,000,000	5,000,000
Preferred Stock, issued (in shares)	0	0
Preferred Stock, outstanding (in shares)	0	0
Common Stock, par value (in dollars per share)	$0.01	$0.01
Common Stock, authorized (in shares)	50,000,000	50,000,000
Common Stock, issued (in shares)	19,049,582	18,903,245
Common Stock, outstanding (in shares)	19,049,582	18,903,245

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Revenues:	'	'	'	'
Product sales	$33,476	$54,041	$79,141	$108,688
Services	5,501	4,024	9,911	6,593
Clinic services	13,143	0	13,143	0
Total revenues	52,120	58,065	102,195	115,281
Cost of revenues:	'	'	'	'
Product sales	6,874	9,933	15,482	20,168
Services	1,895	1,457	3,632	3,088
Clinic services	8,883	0	8,883	0
Total cost of revenues	17,652	11,390	27,997	23,256
Gross profit	34,468	46,675	74,198	92,025
Operating expenses:	'	'	'	'
Engineering and product development	723	814	1,518	1,587
Selling and marketing	30,420	30,468	62,046	59,794
General and administrative	11,452	6,268	19,039	11,927
Total operating expenses	42,595	37,550	82,603	73,308
Operating (loss) profit	-8,127	9,125	-8,405	18,717
Other loss:	'	'	'	'
Interest and other financing expense, net	-175	-134	-321	-3
(Loss) Income before income tax benefit (expense)	-8,302	8,991	-8,726	18,714
Income tax benefit (expense)	822	-1,897	901	-4,408
Net (loss) income	-7,480	7,094	-7,825	14,306
Net (loss) income per share:	'	'	'	'
Basic (in dollars per share)	($0.40)	$0.34	($0.42)	$0.69
Diluted (in dollars per share)	($0.40)	$0.34	($0.42)	$0.68
Shares used in computing net (loss) income per share:	'	'	'	'
Basic (in shares)	18,723,484	20,573,048	18,721,463	20,624,588
Diluted (in shares)	18,723,484	21,033,349	18,721,463	21,084,889
Other comprehensive income :	'	'	'	'
Foreign currency translation adjustments	693	21	1,030	-1,792
Comprehensive (loss) income	($6,787)	$7,115	($6,795)	$12,514

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (Unaudited) (USD $)	Common Stock [Member]	Additional Paid-In Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income [Member]	Total
In Thousands, except Share data, unless otherwise specified
BALANCE at Dec. 31, 2013	$189	$104,954	$53,679	$1,539	$160,361
BALANCE (in shares) at Dec. 31, 2013	18,903,245	'	'	'	18,903,245
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'
Stock-based compensation related to stock options and restricted stock	0	2,486	0	0	2,486
Stock options issued to consultants for services	0	70	0	0	70
Restricted stock issued, net of payroll taxes paid	1	-981	0	0	-980
Restricted stock issued, net of payroll taxes paid (in shares)	146,337	'	'	'	'
Other comprehensive income	0	0	0	1,030	1,030
Net (loss) income	0	0	-7,825	0	-7,825
BALANCE at Jun. 30, 2014	$190	$106,529	$45,854	$2,569	$155,142
BALANCE (in shares) at Jun. 30, 2014	19,049,582	'	'	'	19,049,582

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Cash Flows From Operating Activities:	'	'
Net (loss) income	($7,825)	$14,306
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:	'	'
Depreciation and amortization	4,186	2,959
Provision for doubtful accounts	3,442	2,125
Deferred income taxes	-31	1,982
Stock-based compensation	2,556	2,584
Insurance reserves	-240	0
Loss on disposal of property and equipment	-10	0
Changes in operating assets and liabilities:	'	'
Accounts receivable	6,012	-11,773
Inventories	2,050	-457
Prepaid expenses and other assets	-2,329	3,873
Accounts payable	-7,650	311
Accrued compensation and related expenses	-1,329	473
Other accrued liabilities	-12,620	-7,555
Deferred revenues	-1,371	592
Net cash (used in) provided by operating activities	-15,159	9,420
Cash Flows From Investing Activities:	'	'
Purchases of property and equipment	-154	-474
Investment in (sales of) short term bank deposits	14,113	-3,185
Acquisition, net of cash received	-77,510	0
Lasers placed in service	-3,624	-2,780
Proceeds from sales of property and equipment	20	0
Net cash used in investing activities	-67,155	-6,439
Cash Flows From Financing Activities:	'	'
Payments on notes payable	-451	-418
Repayments of term debt	-131	-14
Proceeds from credit facilities, net	75,000	0
Proceeds from option exercises	0	23
Repurchase of company stock	0	-5,381
Issuance of restricted stock, net of payroll taxes paid	-980	0
Net cash provided by (used in) financing activities	73,438	-5,790
Effect of exchange rate changes on cash	150	-239
Net decrease increase in cash and cash equivalents	-8,726	-3,048
Cash and cash equivalents, beginning of period	45,388	44,348
Cash and cash equivalents, end of period	36,662	41,300
Supplemental information:	'	'
Cash paid for income taxes	812	4,381
Cash paid for interest	$108	$11

The_Company

The Company	6 Months Ended
	Jun. 30, 2014
The Company [Abstract]	'
The Company	'
	Note 1
	The Company:
	Background
	PhotoMedex, Inc. (and its subsidiaries) (the “Company”) is a Global Health products and services company providing integrated disease management and aesthetic solutions to dermatologists, professional aestheticians, ophthalmologists, optometrists, consumers and patients. The Company provides proprietary products and services that address skin diseases and conditions including psoriasis, vitiligo, acne, actinic keratosis photo damage, unwanted hair as well as fixed-site laser vision correction services at our LasikPlus® vision centers.
	On May 12, 2014, PhotoMedex, Inc. (the “Company”) entered into an $85 million senior secured credit facilities (“the Facilities”) with the lenders that are parties thereto (collectively, the “Lenders”) and JP Morgan Chase (“Chase”) as Administrative Agent for the Lenders.  The Facilities included a $10 million revolving credit facility and a $75 million four-year term loan. The Facilities were utilized to refinance the existing term debt with Chase, fund the acquisition of LCA-Vision, Inc. and for working capital and other general corporate purposes.
	Interest is determined at Eurodollar plus a margin between 3.25% and 4.50%. The margin is updated quarterly based on the then-current leverage ratio. The Facilities are secured by a first priority security interest in and lien on all assets of the Company. All current and future subsidiaries are guarantors on the Facilities.
	There are financial covenants including a maximum leverage covenant and a minimum fixed charge covenant, which the Company must maintain. These covenants will be determined quarterly based on a rolling past four quarters of financial data. As of June 30, 2014, the Company failed to meet both financial covenants and is in default of the Facilities. On August 4, 2014, the Company received a notice of default and a reservation of rights from Chase and is engaging a third-party independent advisor to assist the Company in negotiating a longer term solution to the current default.  As a result of the default, the Lenders may accelerate the $85 million outstanding under the Facilities.  The Lenders also may increase the applicable interest on loans under the Facilities by 2%.  As of the date of this report, the Lenders have neither accelerated the outstanding amount nor increased the applicable interest but may do so in the future.
	On December 13, 2011, the Company closed the reverse merger with Radiancy, Inc. Immediately following the reverse merger, the pre-reverse merger shareholders of PhotoMedex, Inc. (“Pre-merged PhotoMedex”) collectively owned approximately 20% of the Company’s outstanding common stock, and the former Radiancy, Inc. stockholders owned approximately 80% of the Company’s outstanding common stock.
	The merger was accounted for as a reverse acquisition with Radiancy treated for accounting purposes as the acquirer. As such, the financial statements of Radiancy, Inc. were treated as the historical financial statements of the Company, with the results of Pre-merged PhotoMedex, Inc. being included from December 14, 2011 and thereafter.
	The Company has a business plan focused on four key components – skilled direct sales force to target Physician and Professional Segments; expertise in global consumer marketing; a full product life cycle model representing the ability to develop and commercialize innovative products from concept through regulatory, physician acceptance, and ultimately marketed directly to the consumer as dictated by normal product-life-cycle evolution and establishing XTRAC centers of excellence in key markets by acquiring a fully paid infrastructure of existing clinics with established high customer service standards and culture. The Company reorganized its business into four operating segments to better align its organization based upon the Company’s management structure, products and services offered, markets served and types of customers.
	On March 3, 2014, PhotoMedex’ wholly-owned subsidiary, Radiancy, Inc., formed a wholly-owned subsidiary in Hong Kong, Radiancy (HK) Limited, through which the Company has started to directly market certain products and services to patients and consumers in selected markets in that region.
	On March 5, 2014, PhotoMedex formed a wholly-owned subsidiary in India, PhotoMedex India Private Limited, through which the Company plans to directly market certain products and services to patients and consumers in selected markets in that country.
	On May 12, 2014, PhotoMedex completed the acquisition of 100% of the shares of LCA-Vision Inc. (“LCA-Vision” or “LCA”), a publicly–traded Delaware corporation. LCA is a provider of fixed-site laser vision corrections services at its LasikPlus® vision centers. Through this acquisition, the Company added an additional operating segment to its organization. The Company plans to begin to directly market certain of its existing products from these centers. The results of operations of LCA-Vision have been included from May 13, 2014 through June 30, 2014 in the PhotoMedex consolidated financial statements. (See Note 2, Acquisition).
	Basis of Presentation:
	The accompanying condensed consolidated financial statements and related notes should be read in conjunction with our consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013 (“fiscal 2013”). The unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) related to interim financial statements. As permitted under those rules, certain information and footnote disclosures normally required or included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted. The financial information contained herein is unaudited; however, management believes all adjustments have been made that are considered necessary to present fairly the results of the Company’s financial position and operating results for the interim periods. All such adjustments are of a normal recurring nature.
	The results for the three and six months ended June 30, 2014 are not necessarily indicative of the results to be expected for the year ending December 31, 2014 or for any other interim period or for any future period.
	Principles of Consolidation
	The consolidated financial statements include the accounts of the Company and the wholly- and majority-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. The LCA-Vision results have been included in the financial statements from May 13, 2014, the day following the closing date of the acquisition.
	Reclassification
	Certain reclassifications from the prior year presentation have been made to conform to the current year presentation. These reclassifications did not have material impact on the Company’s equity, net assets, results of operations or cash flows.
	Revenue Recognition
	The Company recognizes revenues from product sales when the following four criteria have been met: (i) the product has been delivered or the services have been performed and the Company has no significant remaining obligations; (ii) persuasive evidence of an arrangement exists; (iii) the price to the buyer is fixed or determinable; and (iv) collection is reasonably assured. Revenues from product sales are recorded net of provisions for estimated chargebacks, rebates, expected returns and cash discounts.
	The Company ships most of its products FOB shipping point, although from time to time certain customers, for example governmental customers, will insist upon FOB destination. Among the factors the Company takes into account when determining the proper time at which to recognize revenue are (i) when title to the goods transfers and (ii) when the risk of loss transfers. Shipments to distributors or physicians that do not fully satisfy the collection criteria are recognized when invoiced amounts are fully paid or fully assured.
	For revenue arrangements with multiple deliverables within a single, contractually binding arrangement (usually sales of products with separately priced extended warranty), each element of the contract is accounted for as a separate unit of accounting when it provides the customer value on a stand-alone basis and there is objective evidence of the fair value of the related unit.
	With respect to sales arrangements under which the buyer has a right to return the related product, revenue is recognized only if all the following conditions are met: the price is fixed or determinable at the date of sale; the buyer has paid, or is obligated to pay and the obligation is not contingent on resale of the product; the buyer's obligation would not be changed in the event of theft or physical destruction or damage of the product; the buyer has economic substance; the Company does not have significant obligations for future performance to directly bring about resale of the product by the buyer; and the amount of future returns can be reasonably estimated.
	The Company provides a provision for product returns based on the experience with historical sales returns, in accordance with ASC Topic 605-15 with respect to sales of product when a right of return exists. Reported revenues are shown net of the returns provision. Such allowance for sales returns is included in Other Accrued Liabilities. (See Note 8).
	Deferred revenue includes amounts received with respect to extended warranty maintenance, repairs and other billable services and amounts not yet recognized as revenues. Revenues with respect to such activities are deferred and recognized on a straight-line basis over the duration of the warranty period, the service period or when service is provided, as applicable to each service.
	The Company has two distribution channels for its phototherapy treatment equipment. The Company either (i) sells its lasers through a distributor or directly to a physician or (ii) places its lasers in a physician’s office (at no charge to the physician) and generally charges the physician a fee for an agreed upon number of treatments. In some cases, the Company and the customer stipulate to a quarterly or other periodic target of procedures to be performed, and accordingly revenue is recognized ratably over the period.
	When the Company places a laser in a physician’s office, it generally recognizes service revenue based on the number of patient treatments performed, or purchased under a periodic commitment, by the physician. Amounts collected with respect to treatments to be performed through laser-access codes that are sold to physicians free of a periodic commitment, but not yet used, are deferred and recognized as a liability until the physician performs the treatment. Unused treatments remain an obligation of the Company because the treatments can only be performed on Company-owned equipment. Once the treatments are performed, this obligation has been satisfied.
	The Company defers substantially all revenue from sales of laser-access treatment codes ordered by its customers within the last two weeks of the period in determining the amount of procedures performed by its physician-customers. Management believes this approach closely approximates the actual amount of unused treatments that existed at the end of a period.
	Patient Receivables and Allowance for Doubtful Accounts
	The Company, through its subsidiary LCA-Vision, provides financing to some of its patients, including those who could not otherwise obtain third-party financing. The terms of the financing usually require the patient to pay an up-front fee which is intended to cover some or all of the variable costs, and then generally the remainder of the payments are automatically deducted from the patient’s bank account over a period of 12 to 36 months. The Company has recorded an allowance for doubtful accounts as a best estimate of the amount of probable credit losses from the patient financing program. Each month, management reviews and adjusts the allowance based upon past experience with patient financing. The Company charges-off receivables against the allowance for doubtful accounts when it is probable that a receivable will not be recovered. The Company’s policy is to reserve for all patient receivables that remain open past their financial maturity date and to provide reserves for patient collectability rates, recent default activity and the current credit environment. Bad debt expense, on patient receivables, was $111 or less than 1% of the clinics revenues for the period of May 13, 2014 through June 30, 2014.
	For patients that the Company internally finance, the Company charges interest at market rates. Finance and interest charges on patient receivables were $113 for the periods ended June 30, 2014.
	Insurance Reserves
	The Company, through its subsidiary LCA-Vision, maintains a captive insurance company to provide professional liability insurance coverage for claims brought against the Company and its optometrists. In addition, the captive insurance company’s charter allows it to provide professional liability insurance for the Company’s ophthalmologists, none of whom are currently insured by the captive. The Company uses the captive insurance company for both primary insurance and excess liability coverage. A number of claims are now pending with the captive insurance company. Since the captive insurance company is wholly-owned enterprise so it is included in the Company’s consolidated financial statements. As of June 30, 2014, the insurance reserves were $6,111, which represented an actuarially determined estimate of future costs associated with claims filed as well as claims incurred but not yet reported. The actuaries determine loss reserves by comparing the Company’s historical claim experience to comparable insurance industry experience.
	Functional Currency
	The currency of the primary economic environment in which the operations of the Company, its U.S. subsidiaries and Radiancy Ltd., its subsidiary in Israel, are conducted is the US dollar ("$" or "dollars"). Thus, the functional currency of the Company and its subsidiaries (other than the foreign subsidiaries mentioned below) is the dollar (which is also the reporting currency of the Group). The other foreign subsidiaries are each conducted in the local currency of the subsidiary. These currencies include: Great Britain Pounds (GBP), Brazilian Real (BRL), Hong Kong Dollar (HKD), Columbian Peso (COP) and Indian Rupee (INR). Substantially all of the Group's revenues are derived in dollars or in other currencies linked to the dollar. Purchases of most materials and components are carried out in, or linked to the dollar.
	Balances denominated in, or linked to, foreign currencies are stated on the basis of the exchange rates prevailing at the balance sheet date. For foreign currency transactions included in the statement of comprehensive income, the exchange rates applicable to the relevant transaction dates are used. Transaction gains or losses arising from changes in the exchange rates used in the translation of such balances are carried to financing income or expenses.
	Assets and liabilities of foreign subsidiaries, whose functional currency is their local currency, are translated from their respective functional currency to U.S. dollars at the balance sheet date exchange rates. Income and expense items are translated at the average rates of exchange prevailing during the year. Translation adjustments are reflected in the consolidated balance sheets as a component of accumulated other comprehensive income. Deferred taxes are not provided on translation adjustments as the earnings of the subsidiaries are considered to be permanently reinvested.
	Fair Value Measurements
	The Company measures and discloses fair value in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification 820, Fair Value Measurements and Disclosures (“ASC Topic 820”). ASC Topic 820 defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions there exists a three-tier fair-value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
		•	Level 1 – unadjusted quoted prices are available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.
		•	Level 2 – pricing inputs are other than quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data.
		•	Level 3 – pricing inputs are unobservable for the non-financial asset or liability and only used when there is little, if any, market activity for the non-financial asset or liability at the measurement date. The inputs into the determination of fair value require significant management judgment or estimation. Fair value is determined using comparable market transactions and other valuation methodologies, adjusted as appropriate for liquidity, credit, market and/or other risk factors
	This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.
	The fair value of cash and cash equivalents and short term bank deposits are based on its demand value, which is equal to its carrying value. The estimated fair values of notes payable which are based on borrowing rates that are available to the Company for loans with similar terms, collateral and maturity approximate the carrying values. Additionally, the carrying value of all other monetary assets (including long term receivables which bear interest) and liabilities is estimated to be equal to their fair value due to the short-term nature or commercial terms of these instruments.
	Derivative financial instruments are measured at fair value, on a recurring basis. The fair value of derivatives generally reflects the estimated amounts that the Group would receive or pay to terminate the contracts at the reporting dates, based on the prevailing currency prices and the relevant interest rates. Such measurement is classified within Level 2.
	In addition to items that are measured at fair value on a recurring basis, there are also assets and liabilities that are measured at fair value on a nonrecurring basis. Assets and liabilities that are measured at fair value on a nonrecurring basis include certain long-lived assets including goodwill. As such, we have determined that each of these fair value measurements reside within Level 3 of the fair value hierarchy.
	Derivatives
	The group applies the provisions of Accounting Standards Codification ("ASC") Topic 815, Derivatives and Hedging. In accordance with ASC Topic 815, all the derivative financial instruments are recognized as either financial assets or financial liabilities on the balance sheet at fair value. The accounting for changes in the fair value of a derivative financial instrument depends on whether it has been designated and qualifies as part of a hedging relationship and further, on the type of hedging relationship. For derivative financial instruments that are designated and qualify as hedging instruments, a company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, cash flow hedge or a hedge of a net investment in a foreign operation.
	From time to time the Company carries out transactions involving foreign exchange derivative financial instruments (mainly forward exchange contracts) which are designed to hedge the cash flows expected to be paid with respect to forecasted expenses of the Israeli subsidiary (Radiancy) denominated in Israeli local currency (NIS) which is different than its functional currency.
	Such derivatives were not designated as hedging instruments, and accordingly they were recognized in the balance sheet at their fair value, with changes in the fair value carried to the Statement of Comprehensive Income and included in financing income (expenses), net.
	At June 30, 2014, the balance of such derivative instruments amounted to approximately $118 in assets and approximately $93 and $183 were recognized as financing income in the Statement of Comprehensive Income during the three and six months ended June 30, 2014, respectively.
	The nominal amounts of foreign currency derivatives as of June 30, 2014 consist of forward transactions for the exchange of $5,200 into NIS as of June 30, 2014.
	Accrued Enhancement Expense
	The Company, through its subsidiary LCA-Vision, includes participation in its LasikPlus Advantage Plan® (acuity program) in the base surgical price for substantially all of its patients. Under the acuity program, if determined to be medically appropriate, the Company provides post-surgical enhancements free of charge should the patient not achieve the desired visual correction during the initial procedure. Under this pricing structure, the Company accounts for the acuity program similar to a warranty obligation. Accordingly, the Company accrues the costs expected to be incurred to satisfy the obligation as a liability and cost of revenue at the point of sale given its ability to estimate reasonably such costs based on historical trends and the satisfaction of all other revenue recognition criteria.
	This estimate is reviewed throughout the year with consideration to factors such as procedure cost and historical procedure volume when determining the appropriateness of the recorded balance.
	Accrued Warranty Costs
	The Company offers a standard warranty on product sales generally for a one to two-year period. In the case of domestic sales of XTRAC lasers, however, the Company has offered longer warranty periods, ranging from three to four years, in order to meet competition or meet customer demands. The Company provides for the estimated cost of the future warranty claims on the date the product is sold. Total accrued warranty is included in Other Accrued Liabilities on the balance sheet. The activity in the warranty accrual during the six months ended June 30, 2014 and 2013 is summarized as follows:
			June 30,
			2014			2013
			(unaudited)			(unaudited)
	Accrual at beginning of year		$	1,151		$	1,440
Additions charged to warranty expense			398			691
Expiring warranties			(116	)		(281	)
Claims satisfied			(497	)		(655	)
Total			936			1,195
Less: current portion			(864	)		(1,117	)
Accrued extended warranty		$	72		$	78
For extended warranty on the consumer products, see Revenue Recognition above.
Earnings Per Share
Basic and diluted earnings per common share were calculated using the following weighted-average shares outstanding:
		For the Three Months Ended June 30,			For the Six Months Ended
					June 30,
		2014		2013		2014		2013
Weighted-average number of common and common equivalent shares outstanding:
Basic number of common shares outstanding		18,723,484		20,573,048		18,721,463		20,624,588
Dilutive effect of stock options and warrants		-		460,301		-		460,301
Diluted number of common and common stock equivalent shares outstanding		18,723,484		21,033,349		18,721,463		21,084,889
Diluted earnings per share for the three and six months ended June 30, 2014, exclude the impact of common stock options and warrants, totaling 2,550,516 shares, as the effect of their inclusion would be anti-dilutive. Diluted earnings per share for the three and six months ended June 30, 2013, excluded the impact of common stock options and warrants, totaling 2,200,350 shares, as the effect of their inclusion would be anti-dilutive.
Adoption of New Accounting Standards
Effective January 1, 2014, the Company adopted Accounting Standard Update 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force) ("ASU 2013-11").
The amendments in ASU 2013-11 state that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, except as follows: To the extent a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be presented net of deferred tax assets.
ASU 2013-11 applies to all entities that have unrecognized tax benefits when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists at the reporting date. For public companies the amendments in this ASU became effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments were applied prospectively to all unrecognized tax benefits that existed at the effective date.
The adoption of the standard did not have a material impact on the Company's consolidated results of operations and financial condition.
Effective January 1, 2014, the Company adopted Accounting Standards Update 2013-5, Foreign Currency Matters (Topic 830) Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity ("ASU 2013-5").
ASU 2013-5 clarifies that, when a reporting entity (parent) ceases to have a controlling financial interest in a subsidiary or group of assets that is a business (other than a sale of in-substance real estate or conveyance of oil and gas mineral rights) within a foreign entity, the parent is required to apply the guidance in Subtopic 830-30 to release any related cumulative translation adjustment into net income. Accordingly, the cumulative translation adjustment should be released into net income only if the sale or transfer results in the complete or substantially complete liquidation of the foreign entity in which the subsidiary or group of assets had resided. ASU 2013-5 also clarifies that if the business combination achieved in stages relates to a previously held equity method investment (step-acquisition) that is a foreign entity, the amount of accumulated other comprehensive income that is reclassified and included in the calculation of gain or loss shall include any foreign currency translation adjustment related to that previously held investment.
For public companies, the amendments in this Update became effective prospectively for fiscal years (and interim reporting periods within those years) beginning after December 15, 2013. In accordance with the transition requirements, the amendments should be applied prospectively to derecognition events occurring after the effective date. Prior periods should not be adjusted.
The adoption of the standard did not have a material impact on the Company's consolidated results of operations and financial condition.

Acquisition_of_LCAVision_Inc

Acquisition of LCA-Vision Inc	6 Months Ended
	Jun. 30, 2014
Acquisition of LCA-Vision Inc [Abstract]	'
Acquisition of LCA-Vision Inc	'
	Note 2
	Acquisition of LCA-Vision Inc.:
	On May 12, 2014, PhotoMedex Inc., completed the acquisition of 100% of the shares of LCA-Vision, a previously publicly-traded Delaware corporation.
	LCA is a provider of fixed-site laser vision corrections services at its LasikPlus® vision centers. The vision centers provide the staff, facilities, equipment and support services for performing laser vision correction that employs advanced laser technologies to help correct nearsightedness, farsightedness and astigmatism. The vision centers are supported by independent ophthalmologists and credentialed optometrists, as well as other healthcare professionals. Substantially all of LCA’s revenues are derived from the delivery of laser vision correction procedures performed in the vision centers.
	The purchase price of LCA-Vision was $106,552 in aggregate consideration, paid in cash (including the full use of the credit facility), consisting of:
	Fair value LCA-Vision stock (A)		$	103,896
	Fair value of LCA-Vision restricted stock units, including payroll taxes (B)			2,656
	Total purchase price		$	106,552
	A.	Based on 19,347,554 outstanding shares of LCA-Vision common stock at May 12, 2014.
	B.	Based on 476,436 outstanding or deemed to be outstanding restricted stock units of LCA-Vision common stock at May 12, 2014.
	The fair value of the assets acquired and liabilities assumed were based on management estimates and values derived from an outside independent appraisal. The Company expects that the allocation will be finalized within twelve months after the merger. Based on the purchase price allocation, the following table summarizes the estimated provisional fair value amounts of the assets acquired and liabilities assumed at the date of acquisition:
	Cash and cash equivalents		$	29,042
	Current assets, excluding cash and cash equivalents			6,114
	Deferred tax asset, current			1,124
	Property, plant and equipment			17,269
	Identifiable intangible assets			39,050
	Other assets			1,518
	Total assets acquired at fair value			94,117
	Current liabilities			(19,009	)
	Long-term debt			(1,603	)
	Deferred tax liability, long-term			(9,138	)
	Other long-term liabilities			(7,397	)
	Total liabilities assumed			(37,147	)
	Net assets acquired		$	56,970
	The purchase price exceeded the fair value of the net assets acquired by $49,582, which was recorded as goodwill.
	The consolidated results of operations do not include any revenues or expenses related to the LCA-Vision business on or prior to May 13, 2014, the consummation date of the acquisition. The Company’s unaudited pro-forma results for the three and six months ended June 30, 2014 and 2014 summarize the combined results of PhotoMedex and LCA-Vision in the following table, assuming the acquisition had occurred on January 1, 2013 and after giving effect to the acquisition adjustments, including amortization of the tangible and definite-lived intangible assets were acquired in the transaction:
			Three Months Ended June 30,					Six Months Ended June 30,
			2014			2013		2014			2013
			(unaudited)			(unaudited)		(unaudited)			(unaudited)
	Net revenues		$	61,170		$	80,674	$	136,776		$	166,194
	Net income (loss)			(14,734	)		5,762		(16,747	)		12,579
	Net income (loss) per share:
	Basic		$	(0.79	)	$	0.28	$	(0.89	)	$	0.61
	Diluted		$	(0.79	)	$	0.27	$	(0.89	)	$	0.6
	Shares used in calculating net income (loss) per share:
	Basic			18,723,484			20,573,048		18,721,463			20,624,588
	Diluted			18,723,484			21,033,349		18,721,463			21,084,889
	These unaudited pro-forma results have been prepared for comparative purposes only and do not purport to be indicative of the results of operations which would have actually resulted had the acquisition occurred on January 1, 2013, nor to be indicative of future results of operations.

Inventories_net

Inventories, net	6 Months Ended
	Jun. 30, 2014
Inventories, net [Abstract]	'
Inventories, net	'
	Note 3
	Inventories, net:
		30-Jun-14		31-Dec-13
		(unaudited)
	Raw materials and work in progress	$	10,252	$	12,631
	Finished goods		15,366		14,916
	Total inventories, net	$	25,618	$	27,547
	Work-in-process is immaterial, given the Company’s typically short manufacturing cycle, and therefore is disclosed in conjunction with raw materials.

Property_and_Equipment_net

Property and Equipment, net	6 Months Ended
	Jun. 30, 2014
Property and Equipment, net [Abstract]	'
Property and Equipment, net	'
	Note 4
	Property and Equipment, net:
		30-Jun-14			31-Dec-13
		(unaudited)
	Lasers-in-service	$	23,540		$	12,599
	Equipment, computer hardware and software		5,725			4,730
	Furniture and fixtures		1,343			705
	Land and building		2,905			-
	Leasehold improvements		5,725			534
			39,238			18,568
	Accumulated depreciation and amortization		(10,100	)		(8,079	)
	Property and equipment, net	$	29,138		$	10,489
	Depreciation and related amortization expense was $2,390 and $1,343 for the six months ended June 30, 2014 and 2013, respectively.

Patents_and_Licensed_Technolog

Patents and Licensed Technologies, net	6 Months Ended
	Jun. 30, 2014
Patents and Licensed Technologies, net [Abstract]	'
Patents and Licensed Technologies, net	'
	Note 5
	Patents and Licensed Technologies, net:
		30-Jun-14			31-Dec-13
		(unaudited)
	Gross Amount beginning of period	$	15,648		$	15,411
	Additions		98			171
	Translation differences		107			66
	Gross Amount end of period		15,853			15,648
	Accumulated amortization		(5,893	)		(4,816	)
	Patents and licensed technologies, net	$	9,960		$	10,832
	Related amortization expense was $1,040 and $1,020 for the six months ended June 30, 2014 and 2013, respectively.
	Estimated amortization expense for amortizable patents and licensed technologies assets for the next five years is as follows:
	Last six months of 2014	$	1,062
	2015		2,049
	2016		2,059
	2017		909
	2018		899
	Thereafter		2,982
	Total	$	9,960

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets, net	6 Months Ended
	Jun. 30, 2014
Goodwill and Other Intangible Assets, net [Abstract]	'
Goodwill and Other Intangible Assets, net	'
	Note 6
	Goodwill and Other Intangible Assets, net:
	As part of the purchase price allocation for the reverse acquisition in December 2011, the Company recorded goodwill in the amount of $24,005 and definite-lived intangibles in the amount of $12,000. As part of the provisional purchase price allocation for the LCA-Vision acquisition in May 2014, the Company recorded goodwill in the amount of $49,582, indefinite-lived intangibles in the amount of $29,850 and definite-lived intangibles in the amount of $9,200. Goodwill reflects the value or premium of the acquisition price in excess of the fair values assigned to specific tangible and intangible assets. The goodwill which was allocated to the activities of LCA-Vision was recognized as a new reportable segment (“Clinics”). Goodwill and the LCA-Vision trademark name have an indefinite useful life and therefore are not amortized as an expense, but is reviewed at least annually for impairment. The goodwill and other identifiable assets of LCA-Vision are subject to change based upon the final allocation of the purchase price. The purchase price intrinsically recognizes the benefits of leveraging under-utilized clinics by establishing XTRAC centers of excellence in key markets.
		Goodwill			Trademarks
	Balance at January 1, 2014	$	24,930		$	-
	Additions for LCA-Vision acquisition		49,582			29,850
	Translation differences		498			-
	Balance at June 30, 2014	$	75,010		$	29,850
	The Company has no impairment loss on goodwill or indefinite-lived assets as of June 30, 2014.
	Set forth below is a detailed listing of other definite-lived intangible assets:
		30-Jun-14
		(unaudited)
		Trademarks			Customer Relationships			Managed Care Network			Total
	Gross Amount beginning of period	$	5,772		$	6,417		$	-		$	12,189
	Additions		-			-			9,200			9,200
	Translation differences		46			72			-			118
	Gross Amount end of period		5,818			6,489			9,200			21,507
	Accumulated amortization		(1,479	)		(1,649	)		(144	)		(3,272	)
	Net Book Value	$	4,339		$	4,840		$	9,056		$	18,235
		31-Dec-13
		Trademarks			Customer Relationships			Managed Care Network			Total
	Gross Amount beginning of period	$	5,744		$	6,372		$	-		$	12,116
	Translation differences		28			45			-			73
	Gross Amount end of period		5772			6,417			-			12,189
	Accumulated amortization		(1,178	)		(1,310	)		-			(2,488	)
	Net Book Value	$	4,594		$	5,107		$	-		$	9,701
	Related amortization expense was $756 and $600 for the periods ended June 30, 2014 and 2013, respectively. Customer Relationships embody the value to the Company of relationships that Pre-merged PhotoMedex had formed with its customers. Trademarks include the tradenames and various trademarks associated with Pre-merged PhotoMedex products (e.g. “XTRAC”, “Neova” “Omnilux” and “Lumiere”). Additions to Trademarks include the tradename/trademark associated with LCA-Vision services. This tradename is considered to have an indefinite live. Managed Care Network relates to relationships with leading managed care providers (i.e. employee vision plans) that refers business to LCA-Vision. The Managed Care Network is to be amortized over a ten-year life.
	Estimated amortization expense for the above amortizable intangible assets for the next five years is as follows:
	Last six months of 2014	$	1,175
	2015		2,350
	2016		2,350
	2017		2,350
	2018		2,350
	Thereafter		7,660
	Total	$	18,235

Accrued_Compensation_and_relat

Accrued Compensation and related expenses	6 Months Ended
	Jun. 30, 2014
Accrued Compensation and related expenses [Abstract]	'
Accrued Compensation and related expenses	'
	Note 7
	Accrued Compensation and related expenses:
		30-Jun-14		31-Dec-13
		(unaudited)
	Accrued payroll and related taxes	$	1,932	$	707
	Accrued vacation		442		290
	Accrued commissions and bonus		1,600		2,233
	Total accrued compensation and related expense	$	3,974	$	3,230

Other_Accrued_Liabilities

Other Accrued Liabilities	6 Months Ended
	Jun. 30, 2014
Other Accrued Liabilities [Abstract]	'
Other Accrued Liabilities	'
	Note 8
	Other Accrued Liabilities:
			30-Jun-14			31-Dec-13
			(unaudited)
	Accrued warranty, current, see Note 1		$	864		$	1,094
	Accrued taxes, net			1,753			1,023
	Accrued sales returns (1)			6,547			16,046
	Insurance liability reserves, current			805			-
	Accrued enhancement expenses, current			836			-
	Other accrued liabilities			5,162			3,869
	Total other accrued liabilities		$	15,967		$	22,032
	(1)	The activity in the sales returns liability account was as follows:
			Six Months Ended June 30,
			2014			2013
			(unaudited)			(unaudited)
	Balance at beginning of year		$	16,046		$	11,901
	Additions that reduce net sales			18,636			17,156
	Deductions from reserves			(28,135	)		(21,117	)
	Balance at end of period		$	6,547		$	7,940

LongTerm_Other_Liabilities

Long-Term Other Liabilities	6 Months Ended
	Jun. 30, 2014
Long-Term Other Liabilities [Abstract]	'
Long-Term Other Liabilities	'
	Note 9
	Long-Term Other Liabilities:
		30-Jun-14		31-Dec-13
		(unaudited)
	Long-term insurance liability reserves, net of current portion	$	5,305	$	-
	Accrued enhancement expenses, net of current portion		1,140		-
	Other liabilities		834		61
	Total long-term liabilities	$	7,279	$	61

Longterm_Debt

Long-term Debt	6 Months Ended
	Jun. 30, 2014
Long-term Debt [Abstract]	'
Long-term Debt	'
	Note 10
	Long-term Debt:
	In the following table is a summary of the Company’s long-term debt:
		30-Jun-14			31-Dec-13
		(unaudited)
	Senior-secured credit facilities, net of unamortized debt discount of $606	$	84,394		$	-
	Term note		-			10,000
	Third-party debt		1,472			-
	Sub-total		85,866			10,000
	Less: current portion		85,185			10,000
	Long-term debt	$	681		$	-
	Senior Secured Credit Facilities
	On May 12, 2014, PhotoMedex, Inc. (the “Company”) entered into an $85 million senior secured credit facilities (“the Facilities”) with the lenders that are parties thereto (collectively, the “Lenders”) and JP Morgan Chase (“Chase”) as Administrative Agent for the Lenders.  The Facilities included a $10 million revolving credit facility and a $75 million four-year term loan. The Facilities were utilized to refinance the existing term debt with Chase, fund the acquisition of LCA-Vision, Inc. and for working capital and other general corporate purposes.
	Interest is determined at Eurodollar plus a margin between 3.25% and 4.50%. The margin is updated quarterly based on the then-current leverage ratio. The Facilities are secured by a first priority security interest in and lien on all assets of the Company. All current and future subsidiaries are guarantors on the Facilities.
	There are financial covenants including a maximum leverage covenant and a minimum fixed charge covenant, which the Company must maintain. These covenants will be determined quarterly based on a rolling past four quarters of financial data. As of June 30, 2014, the Company failed to meet both financial covenants and is in default of the Facilities. On August 4, 2014, the Company received a notice of default and a reservation of rights from Chase and is engaging a third-party independent advisor to assist the Company in negotiating a longer term solution to the current default.  As a result of the default, the Lenders may accelerate the $85 million outstanding under the Facilities.  The Lenders also may increase the applicable interest on loans under the Facilities by 2%.  As of the date of this report, the Lenders have neither accelerated the outstanding amount nor increased the applicable interest but may do so in the future.
	Term-Note Credit Facility
	In December 2013, the Company, through its subsidiary, Radiancy, Inc., entered into a term-note facility with JP Morgan Chase (“Chase”). The facility has maximum principal amount of $15 million and is for a term of one year. As of December 31, 2013, the Company had total borrowings of $10 million under this facility. The stated interest rate for any draw under the credit facility was set as the greater of (i) prime rate, (ii) federal funds effective rate plus .5% or (iii) LIBOR plus 2.5%. Each draw has a repayment period of one year with principal due at maturity, although any draw may be paid early with penalty. This term-note was cancelled at the time the senior secured credit facilities were entered into.
	Third-party debt
	Through the acquisition of LCA-Vision, the Company assumed debt to a third party for purchases of equipment. LCA-Vision had outstanding debt related to the 2013 purchases of excimer lasers for all of the full-service vision centers. The terms of the financing are over an original 36-month term at a fixed interest rate of 3.5%. The financing agreement does not contain any financial covenants and is secured by the excimer lasers.
	The following table summarizes the future minimum payments that the Company expects to make for long-term debt:
	Last six months of 2014	$	7,892
	2015		17,405
	2016		19,025
	2017		20,900
	2018		21,250
	Total minimum payments		86,472
	Less: unamortized discount		(606	)
	Present value of total minimum obligations	$	85,866

Income_Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2014
Income Taxes [Abstract]	'
Income Taxes	'
	Note 11
	Income Taxes:
	The Company's effective tax rate is dependent upon the geographic distribution of its earnings or losses (mainly between US and Israel).
	The difference between the Company's effective tax rates for the three and six month periods ended June 30, 2014 and the U.S. Federal statutory rate (34%) resulted primarily from Pre-merged PhotoMedex current operations which have generated losses, which reduced the overall corporate tax expense and which will have effect on current tax expense when the Company elected to file a U.S. consolidated income tax return. In addition, the Israeli and UK subsidiaries’ earnings are taxed at rates lower than the federal statutory rate (Israel 16% preferred income tax rate, 26.5% standard corporation tax rate and in the UK 20%).
	The application of income tax law is inherently complex. Laws and regulations in this area are voluminous and can be ambiguous; the Company is, therefore, obliged to make many subjective assumptions and judgments regarding the application of such laws and regulations to its facts and circumstances. In addition, interpretations of and guidance surrounding income tax laws and regulations are subject to changes over time. Any changes in the Company's subjective assumptions and judgments could materially affect amounts recognized in its consolidated balance sheets and statements of income.

Commitments_and_contingencies

Commitments and contingencies	6 Months Ended
	Jun. 30, 2014
Commitments and contingencies [Abstract]	'
Commitments and contingencies	'
	Note 12
	Commitments and contingencies:
	With the acquisition of LCA-Vision, the Company has additional operating lease obligations. The total value of these lease obligations are $19,456, with $5,910 due less than 1 year; $9,149 due between 1 to 3 years; $3,693 due 3 to 5 years and $704 due more than 5 years from now.
	The Company’s subsidiary, LCA-Vision, is in a business that results in malpractice lawsuits. LCA-Vison is insured through the captive insurance company to provide coverage for current claims brought against LCA-Vision. The captive insurance company is used for both primary insurance and excess liability coverage. A number of claims are now pending with the captive insurance company.
	The loss reserves are based on the Company’s historical claim experience, comparable industry experience and recent trends that would impact the ultimate settlement of claims. However, due to the uncertainties inherent in the determination of these liabilities, the ultimate settlement of claims incurred through June 30, 2014 could differ from the amounts recorded. At June 30, 2014, the Company maintained insurance reserves of $6,111 of which $805 is considered to be current. Although the insurance reserve reflects management’s best estimate of the amount of probable loss, management believes the range of loss that is reasonably possible to have been incurred to be approximately $4,383 to $12,758 at June 30, 2104. Any adjustments to these estimates are recorded in the period determined.
	During the year ended December 31, 2013, Radiancy, Inc., a wholly-owned subsidiary of PhotoMedex, commenced legal action against Viatek Consumer Products Group, Inc., over Viatek’s Pearl and Samba hair removal products which Radiancy believes infringe the intellectual property covering its no!no! hair removal devices. The first suit, which was filed in the United States Federal Court, Southern District of New York, includes claims against Viatek for patent infringement, trademark and trade dress infringement, and false and misleading advertising. A second suit against Viatek was filed in Canada, where the Pearl is offered on that country’s The Shopping Channel, alleging trademark and trade dress infringement, and false and misleading advertising. Viatek’s response contains a variety of counterclaims and affirmative defenses against both Radiancy and its parent company PhotoMedex, including, among other counts, claims regarding the invalidity of Radiancy’s patents and antitrust allegations regarding Radiancy’s conduct.
	On March 28, 2014, the Court granted the Company’s motion and dismissed our parent company, PhotoMedex, from the lawsuit. The Court also dismissed certain counterclaims and affirmative defenses asserted by Viatek, including Viatek’s counterclaims against Radiancy for antitrust, unfair competition, and tortious interference with business relationships and Viatek’s affirmative defenses of unclean hands and inequitable conduct before the U.S. Patent and Trademark Office in procuring its patent. Radiancy had also moved for sanctions against Viatek for failure to provide meaningful and timely responses to Radiancy’s discovery requests; on April 1, 2014, the Court granted Radiancy’s motion for sanctions against Viatek. Viatek appealed both the sanctions ruling and the dismissal of Viatek’s counterclaims and defenses from the case, as well as PhotoMedex’s dismissal as a plaintiff; the Court has denied those appeals in their entirety. The Court also appointed a Special Master to oversee discovery. As of August 9, 2014, the case remains in the discovery phase of the litigation. Radiancy, and PhotoMedex, had moved to dismiss PhotoMedex from the case, and to dismiss the counterclaims and affirmative defenses asserted by Viatek. At this time, the amount of any loss, or range of loss, cannot be reasonably estimated as the case is still in the early stages of discovery to determine the validity of any claim or claims made by Viatek. Therefore, the Company has not recorded any reserve or contingent liability related to this particular legal matter. However, in the future, as the case progresses, the Company may be required to record a contingent liability or reserve for this matter.
	On December 20, 2013, PhotoMedex, Inc. was served with a putative class action lawsuit filed in the United States District Court for the Eastern District of Pennsylvania against the Company and its two top executives, Dolev Rafaeli, Chief Executive Officer, and Dennis M. McGrath, President and Chief Financial Officer. The suit, filed by Mr. Guy Ratz, a former employee of Radiancy (Israel) Ltd., a wholly-owned subsidiary of the Company, alleges various violations of the Federal securities laws between November 7, 2012 and November 14, 2013, including that the Company and its officers made false and misleading statements or failed to disclose material facts concerning the Company’s business. Two other shareholders filed suit through other firms; the Asbestos Workers Local 14 Pension Fund was appointed the lead plaintiff in this case. An amended complaint was filed by the plaintiffs on April 15, 2014. The Company filed a motion to dismiss the case in its entirety; briefing continues on that motion. The complaint seeks certification of the putative class as well as an unspecified amount of monetary damages, pre-and post-judgment interest and attorneys’ fees, expert witness fees and other costs. The Company and its officers intend to vigorously defend themselves against this lawsuit. At this time, the amount of any loss, or range of loss, cannot be reasonably estimated as the cases have only been initiated and no discovery has been conducted to determine the validity of any claim or claims made by plaintiffs. Therefore, the Company has not recorded any reserve or contingent liability related to these particular legal matters. However, in the future, as the cases progress, the Company may be required to record a contingent liability or reserve for these matters.
	Six putative class-action lawsuits were filed in connection with PhotoMedex’s proposed acquisition of LCA-Vision, Inc. Two of those suits were filed in the Court of Chancery of the State of Delaware and four were filed in the Court of Common Pleas of Hamilton County, Ohio. All cases assert claims against LCA-Vision, Inc., and a mix of other defendants, including LCA’s chief executive officer and directors, PhotoMedex, and Gatorade Acquisition Corp., a wholly owned subsidiary of PhotoMedex. The complaints generally allege that the proposed acquisition undervalued LCA and deprived LCA’s shareholders of the opportunity to participate in LCA’s long-term financial prospects, that the “go shop” and “deal-protection” provisions of the Merger Agreement were designed to prevent LCA from soliciting or receiving competing offers, that LCA’s Board breached its fiduciary duties and failed to maximize that company’s stockholder value, and that LCA, PhotoMedex, and Gatorade aided and abetted the LCA defendants’ alleged breaches of duty. The complaints seek injunctive relief, unspecified damages, and other relief. The Ohio plaintiffs agreed to consolidate their suits and take the lead on this matter, although the Ohio Court did not formally consolidate the suits until April 24, 2014. The Delaware suits were consolidated on March 25, 2014; on or around that same date, the parties reached an agreement by which LCA and the other defendants agreed to produce certain discovery to the plaintiffs on an expedited basis. On April 30, 2014, the Ohio plaintiffs (with the Delaware plaintiffs’ concurrence) agreed to withdraw their motion for a preliminary injunction and not seek to enjoin the stockholder vote or the consummation of the merger in return for LCA’s agreement to make certain supplemental disclosures related to the merger. Those supplemental disclosures were filed by LCA under a Form 8-K on April 30, 2014. This agreement did not affect the terms of the Merger Agreement or the amount of consideration LCA stockholders will be entitled to receive in the merger. The Company intends to continue to vigorously defend itself in the lawsuits if the parties cannot enter into a formal stipulation of settlement. At this time, the amount of any loss, or range of loss, cannot be reasonably estimated, as the cases have only been recently initiated and little discovery has been conducted to determine the validity of any claim or claims made by plaintiffs. Therefore, the Company has not recorded any reserve or contingent liability related to these particular legal matters. However, in the future, as the cases progress, the Company may be required to record a contingent liability or reserve for these matters if the cases cannot be resolved.
	On April 25, 2014, a putative class action lawsuit was filed in the United States District Court for the District of Columbia against the Company’s subsidiary, Radiancy, Inc. and Dolev Rafaeli, Radiancy’s President. The suit was filed by Jan Mouzon and twelve other customers residing in ten different states who purchased Radiancy’s no!no! Hair products. It alleges various violations of state business and consumer protection codes including false and misleading advertising, unfair trade practices, and breach of express and implied warranties. The complaint seeks certification of the putative class, or, alternatively, certification as subclasses of plaintiffs residing in those specific states. The complaint also seeks an unspecified amount of monetary damages, pre-and post-judgment interest and attorneys’ fees, expert witness fees and other costs. Dr. Rafaeli was served with the Complaint on May 5, 2014; to date, Radiancy, has not been served. Radiancy and its officers intend to vigorously defend themselves against this lawsuit. At this time, the amount of any loss, or range of loss, cannot be reasonably estimated as the case has only been initiated and no discovery has been conducted to determine the validity of any claim or claims made by plaintiffs. Therefore, the Company has not recorded any reserve or contingent liability related to these particular legal matters. However, in the future, as the cases progress, the Company may be required to record a contingent liability or reserve for these matters.
	On June 30, 2014, the Company’s subsidiary, Radiancy, Inc., was served with a putative class action lawsuit filed in the Superior Court in the State of California, County of Kern. The suit was filed by April Cantley, who purchased Radiancy’s no!no! Hair products. It alleges various violations of state business and consumer protection codes including false and misleading advertising, breach of express and implied warranties and breach of the California
	Legal Remedies Act. The complaint seeks certification of the putative class, which consists of customers in the State of California who purchased the no!no! Hair devices. The complaint also seeks an unspecified amount of monetary damages, pre-and post-judgment interest and attorneys’ fees, expert witness fees and other costs. Radiancy and its officers intend to vigorously defend themselves against this lawsuit. At this time, the amount of any loss, or range of loss, cannot be reasonably estimated as the case has only been initiated and no discovery has been conducted to determine the validity of any claim or claims made by plaintiffs. Therefore, the Company has not recorded any reserve or contingent liability related to these particular legal matters. However, in the future, as the cases progress, the Company may be required to record a contingent liability or reserve for these matters.
	The Company was served on July 29, 2014 with an application to certify a class action, filed in Israel District Court for Tel Aviv against the Company and its two top executives, Dolev Rafaeli, Chief Executive Officer, and Dennis M. McGrath, President and Chief Financial Officer. Under Israeli procedures, an application is filed with the Court, the Company has 90 days to submit its response, and then the Court reviews the application and the response and determines whether to certify the application as a class action. The application, served by a shareholder of the Company, alleges various violations of the Israeli Securities Law 5728-1968, including that the Company and its officers made false and/or misleading statements or failed to disclose material facts in its public reports concerning the Company’s business, and therefore influenced the Company's share price. The plaintiff seeks class action status to include all purchasers of the Company’s stock between May 3, 2012 and November 6, 2013, specifying an amount in monetary damages of 145 Million New Israeli Shekels or $42,050,000. The plaintiff also seeks pre-and post-judgment interest and attorneys’ fees and other costs. The Company and its officers are already parties to a lawsuit containing similar allegations filed in the United States District Court for the Eastern District of Pennsylvania on December 20, 2013, and intend to vigorously defend themselves against both actions.  At this time, the amount of any loss, or range of loss, cannot be reasonably estimated as the case has only been initiated and no discovery has been conducted to determine the validity of any claim or claims made and any damages stated by plaintiffs. Therefore, the Company has not recorded any reserve or contingent liability related to these particular legal matters. However, in the future, as the cases progress, the Company may be required to record a contingent liability or reserve for these matters. From time to time in the ordinary course of our business, we and certain of our subsidiaries are involved in certain other legal actions and claims, including product liability, consumer, commercial, tax and governmental matters, and claims regarding false advertising and product efficacy which were already raised and reviewed in the Tria litigation. We believe, based on discussions with legal counsel, that these other litigations and claims will likely be resolved without a material effect on our consolidated financial position, results of operations or liquidity. However, litigation is inherently unpredictable, and excessive verdicts can result from litigation. Although we believe we have substantial defenses in these matters, we may, in the future, incur judgments or enter into settlements of claims that could have a material adverse effect on our results of operations in a particular period.

Employee_Stock_Benefit_Plans

Employee Stock Benefit Plans	6 Months Ended
	Jun. 30, 2014
Employee Stock Benefit Plans [Abstract]	'
Employee Stock Benefit Plans	'
	Note 13
	Employee Stock Benefit Plans:
	Post-Reverse Merger
	Following the closing of the December 2011 reverse acquisition, the previous Non-Employee Director Stock Option Plan of PhotoMedex (the acquired entity) was adopted by the group. This plan has authorized 120,000 shares; of which 7,000 shares had been issued or were reserved for issuance as awards of shares of common stock, and 14,578 shares were reserved for outstanding stock options. On July 31, 2014, the shareholders approved an increase in the authorized shares to 370,000 shares under the stock based benefit plan.
	In addition, following the closing of the December 2011 reverse acquisition, the previous 2005 Equity Compensation Plan (“2005 Equity Plan”) of Pre-merged PhotoMedex (the acquired entity) was also adopted for use by the group. The 2005 Equity Plan has authorized 3,000,000 shares, of which 867,432 shares had been issued or were reserved for issuance as awards of shares of common stock, and 1,293,601 shares were reserved for outstanding options. On July 31, 2014, the shareholders approved an increase in the authorized shares to 6,000,000 shares under the stock based benefit plan.
	Stock option activity under all of the Company’s share-based compensation plans for the six months ended June 30, 2014 was as follows:
			Number of			Weighted Average Exercise Price
			Options
	Outstanding, January 1, 2014			1,132,678		$	16.51
	Granted			180,500			14.11
	Exercised			-			-
	Cancelled			(4,999	)		58.63
	Outstanding, June 30, 2014			1,308,179		$	16.02
	Options exercisable at June 30, 2014			517,179		$	16.45
	At June 30, 2014, there was $9,693 of total unrecognized compensation cost related to non-vested option grants and stock awards that is expected to be recognized over a weighted-average period of 2.8 years. The intrinsic value of options outstanding and exercisable at June 30, 2014 was not significant.
	The Company calculates expected volatility for a share-based grants based on historic daily stock price observations of its common stock. For estimating the expected term of share-based grants made in the three and six months ended June 30, 2014, the Company has adopted the simplified method. The Company has used historical data to estimate expected employee behaviors related to option exercises and forfeitures and included these expected forfeitures as a part of the estimate of expense as of the grant date.
	The Company uses the Black-Scholes option-pricing model to estimate fair value of grants of stock options with the following weighted-average assumptions:
		Three Months Ended June 30, 2014		Six Months Ended June 30, 2014
	Risk-free interest rate	2.21%		2.17%
	Volatility	76.61%		78.41%
	Expected dividend yield	0%		0%
	Expected life	5.5 years		5.5 years
	Estimated forfeiture rate	0%		0%
	With respect to grants of options, the risk-free rate of interest is based on the U.S. Treasury rates appropriate for the expected term of the grant or award.
	On April 17, 2014, the Company issued 5,000 shares of common stock to a non-employee director for an aggregate fair value of $75.
	On May 12, 2014, the Company granted 141,337 restricted stock units to three LCA employees as part of their respective employment agreements related to the acquisition. These restricted shares have a purchase price of $0.01 per share and vest, and cease to be subject to the Company’s right of repurchase, over a three-year period. The Company determined the fair value of the awards to be the fair value of the Company’s common stock on the date of issuance less the value paid for the award. The Company also granted an aggregate of 109,000 options to purchase common stock to a number of employees with a strike price of $13.70, which was higher than the quoted market value of our stock at the date of grants. The options vest over four years and expire ten years from the date of grant. The aggregate fair value of the options granted was $975.
	On February 27, 2014, the Company granted an aggregate of 71,500 options to purchase common stock to a number of employees and consultants with a strike price of $14.80, which was higher than the quoted market value of our stock at the date of grants. The options vest over five years and expire ten years from the date of grant. The aggregate fair value of the options granted was $718.
	Total stock based compensation expense was $2,556 and $2,584 for the six months ended June 30, 2014 and 2013, including amounts relating to consultants.

Business_Segments_and_Geograph

Business Segments and Geographic Data	6 Months Ended
	Jun. 30, 2014
Business Segments and Geographic Data [Abstract]	'
Business Segments and Geographic Data	'
	Note 14
	Business Segments and Geographic Data:
	Following the acquisition of LCA-Vision, the Company’s business was aligned into four operating segments based upon the Company’s management structure, products and services offered, markets served and types of customers, as follows: The Consumer segment derives its revenues from the design, development, manufacturing and selling of long-term hair reduction and acne consumer products. The Physician Recurring segment derives its revenues from the XTRAC procedures performed by dermatologists, the sales of skincare products, the sales of surgical disposables and accessories to hospitals and surgery centers and on the repair, maintenance and replacement parts on our various products. The Professional segment generates revenues from the sale of equipment, such as lasers, medical and esthetic light and heat-based products and LED products. The Clinics segment generates revenues from services performed and products sold in our vision centers. Management reviews financial information presented on an operating segment basis for the purposes of making certain operating decisions and assessing financial performance.
	Unallocated operating expenses include costs that are not specific to a particular segment but are general to the group; included are expenses incurred for administrative and accounting staff, general liability and other insurance, professional fees and other similar corporate expenses. Unallocated assets include cash and cash equivalents, prepaid expenses and deposits.
	The following tables reflect results of operations from our business segments for the periods indicated below:
	Three Months Ended June 30, 2014 (unaudited)
		Consumer			Physician Recurring			Professional			Clinics			Total
	Revenues	$	28,453		$	8,607		$	1,917		$	13,143		$	52,120
	Costs of revenues		3,983			3,425			1,361			8,883			17,652
	Gross profit		24,470			5,182			556			4,260			34,468
	Gross profit %		86	%		60.2	%		29	%		32.4	%		66.1	%
	Allocated operating expenses:
	Engineering and product development		305			257			161			-			723
	Selling and marketing expenses		23,223			4,268			274			2,655			30,420
	Unallocated operating expenses		-			-			-			-			11,452
			23,528			4,525			435			2,655			42,595
	Income (loss) from operations		942			657			121			1,605			(8,127	)
	Interest  and other financing expense, net		-			-			-			-			(175	)
	Net income (loss) before taxes	$	942		$	657		$	121		$	1,605		$	( 8,302	)
	Three Months Ended June 30, 2013 (unaudited)
		Consumer			Physician Recurring			Professional			Clinics			Total
	Revenues	$	48,673		$	7,376		$	2,016		$	-		$	58,065
	Costs of revenues		7,174			3,014			1,202			-			11,390
	Gross profit		41,499			4,362			814			-			46,675
	Gross profit %		85.3	%		59.1	%		40.4	%		N/A			80.4	%
	Allocated operating expenses:
	Engineering and product development		279			317			218			-			814
	Selling and marketing expenses		26,703			3,233			532			-			30,468
	Unallocated operating expenses		-			-			-			-			6,268
			26,982			3,550			750			-			37,550
	Income from operations		14,517			812			64			-			9,125
	Interest and other financing expense, net		-			-			-			-			(134	)
	Net income before taxes	$	14,517		$	812		$	64		$	-		$	8,991
	Six Months Ended June 30, 2014 (unaudited)
		Consumer			Physician Recurring			Professional			Clinics			Total
	Revenues	$	69,323		$	15,826		$	3,903		$	13,143		$	102,195
	Costs of revenues		10,233			6,255			2,626			8,883			27,997
	Gross profit		59,090			9,571			1,277			4,260			74,198
	Gross profit %		85.2	%		60.5	%		32.7	%		32.4	%		72.6	%
	Allocated operating expenses:
	Engineering and product development		592			567			359			-			1,518
	Selling and marketing expenses		50,381			8,279			731			2,655			62,046
	Unallocated operating expenses		-			-			-			-			19,039
			50,973			8,846			1,090			2,655			82,603
	Income from operations		8,117			725			187			1,605			(8,405	)
	Interest and other financing expense, net		-			-			-			-			(321	)
	Net income (loss)before taxes	$	8,117		$	725		$	187		$	1,605		$	(8,726	)
	Six Months Ended June 30, 2013 (unaudited)
		Consumer			Physician Recurring			Professional			Clinics			Total
	Revenues	$	97,733			13,331		$	4,217		$	-		$	115,281
	Costs of revenues		14,691			5,945			2,620			-			23,256
	Gross profit		83,042			7,386			1,597			-			92,025
	Gross profit %		85	%		55.4	%		37.9	%		N/A			79.8	%
	Allocated operating expenses:
	Engineering and product development		497			641			449			-			1,587
	Selling and marketing expenses		52,334			6,407			1,053			-			59,794
	Unallocated operating expenses		-			-			-			-			11,927
			52,831			7,048			1,502			-			73,308
	Income from operations		30,211			338			95			-			18,717
	Interest  and other financing expense, net		-			-			-			-			(3	)
	Net income before taxes	$	30,211		$	338		$	95		$	-		$	18,714
	For the three and six months ended June 30, 2014 and 2013 (unaudited), net revenues by geographic area were as follows:
		Three Months Ended						Six Months Ended
June 30,					June 30,
	2014			2013			2014			2013
North America 1	$	41,803		$	42,033		$	81,776		$	86,932
Asia Pacific 2		2,638			9,440			5,015			15,202
Europe (including Israel)		7,084			5,861			14,492			11,494
South America		595			731			912			1,653
	$	52,120		$	58,065		$	102,195		$	115,281
1 United States	$	38,612		$	37,329		$	73,379		$	75,336
1 Canada	$	3,191		$	4,704		$	8,397		$	11,596
2  Japan	$	290		$	7,452		$	988		$	11,715
As of June 30, 2014 and December 31, 2013, long-lived assets by geographic area were as follows:
	30-Jun-14			31-Dec-13
	(unaudited)
North America	$	27,859		$	9,119
Asia Pacific		4			-
Europe (including Israel)		1,270			1,370
South America		5			-
	$	29,138		$	10,489
The Company discusses segmental details in its Management Discussion and Analysis found elsewhere in this Quarterly Report on Form 10-Q.

Significant_Customer_Concentra

Significant Customer Concentration	6 Months Ended
	Jun. 30, 2014
Significant Customer Concentration [Abstract]	'
Significant Customer Concentration	'
	Note 15
	Significant Customer Concentration:
	No customer was more than 10% of total company revenues for the three and six months ended June 30, 2014. For the three and six months ended June 30, 2013, there were two customers more than 10% of revenues.
		Three Months Ended June 30, 2013	Six Months Ended June 30, 2013
	Customer A	11%	11%
	Customer B	12%	9%

The_Company_Policies

The Company (Policies)	6 Months Ended
	Jun. 30, 2014
The Company [Abstract]	'
Basis of Presentation	'
	Basis of Presentation:
	The accompanying condensed consolidated financial statements and related notes should be read in conjunction with our consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013 (“fiscal 2013”). The unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) related to interim financial statements. As permitted under those rules, certain information and footnote disclosures normally required or included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted. The financial information contained herein is unaudited; however, management believes all adjustments have been made that are considered necessary to present fairly the results of the Company’s financial position and operating results for the interim periods. All such adjustments are of a normal recurring nature.
	The results for the three and six months ended June 30, 2014 are not necessarily indicative of the results to be expected for the year ending December 31, 2014 or for any other interim period or for any future period.
Principles of Consolidation	'
	Principles of Consolidation
	The consolidated financial statements include the accounts of the Company and the wholly- and majority-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. The LCA-Vision results have been included in the financial statements from May 13, 2014, the day following the closing date of the acquisition.
Reclassification	'
	Reclassification
	Certain reclassifications from the prior year presentation have been made to conform to the current year presentation. These reclassifications did not have material impact on the Company’s equity, net assets, results of operations or cash flows.
Revenue Recognition	'
	Revenue Recognition
	The Company recognizes revenues from product sales when the following four criteria have been met: (i) the product has been delivered or the services have been performed and the Company has no significant remaining obligations; (ii) persuasive evidence of an arrangement exists; (iii) the price to the buyer is fixed or determinable; and (iv) collection is reasonably assured. Revenues from product sales are recorded net of provisions for estimated chargebacks, rebates, expected returns and cash discounts.
	The Company ships most of its products FOB shipping point, although from time to time certain customers, for example governmental customers, will insist upon FOB destination. Among the factors the Company takes into account when determining the proper time at which to recognize revenue are (i) when title to the goods transfers and (ii) when the risk of loss transfers. Shipments to distributors or physicians that do not fully satisfy the collection criteria are recognized when invoiced amounts are fully paid or fully assured.
	For revenue arrangements with multiple deliverables within a single, contractually binding arrangement (usually sales of products with separately priced extended warranty), each element of the contract is accounted for as a separate unit of accounting when it provides the customer value on a stand-alone basis and there is objective evidence of the fair value of the related unit.
	With respect to sales arrangements under which the buyer has a right to return the related product, revenue is recognized only if all the following conditions are met: the price is fixed or determinable at the date of sale; the buyer has paid, or is obligated to pay and the obligation is not contingent on resale of the product; the buyer's obligation would not be changed in the event of theft or physical destruction or damage of the product; the buyer has economic substance; the Company does not have significant obligations for future performance to directly bring about resale of the product by the buyer; and the amount of future returns can be reasonably estimated.
	The Company provides a provision for product returns based on the experience with historical sales returns, in accordance with ASC Topic 605-15 with respect to sales of product when a right of return exists. Reported revenues are shown net of the returns provision. Such allowance for sales returns is included in Other Accrued Liabilities. (See Note 8).
	Deferred revenue includes amounts received with respect to extended warranty maintenance, repairs and other billable services and amounts not yet recognized as revenues. Revenues with respect to such activities are deferred and recognized on a straight-line basis over the duration of the warranty period, the service period or when service is provided, as applicable to each service.
	The Company has two distribution channels for its phototherapy treatment equipment. The Company either (i) sells its lasers through a distributor or directly to a physician or (ii) places its lasers in a physician’s office (at no charge to the physician) and generally charges the physician a fee for an agreed upon number of treatments. In some cases, the Company and the customer stipulate to a quarterly or other periodic target of procedures to be performed, and accordingly revenue is recognized ratably over the period.
	When the Company places a laser in a physician’s office, it generally recognizes service revenue based on the number of patient treatments performed, or purchased under a periodic commitment, by the physician. Amounts collected with respect to treatments to be performed through laser-access codes that are sold to physicians free of a periodic commitment, but not yet used, are deferred and recognized as a liability until the physician performs the treatment. Unused treatments remain an obligation of the Company because the treatments can only be performed on Company-owned equipment. Once the treatments are performed, this obligation has been satisfied.
	The Company defers substantially all revenue from sales of laser-access treatment codes ordered by its customers within the last two weeks of the period in determining the amount of procedures performed by its physician-customers. Management believes this approach closely approximates the actual amount of unused treatments that existed at the end of a period.
Patient Receivables and Allowance for Doubtful Accounts	'
	Patient Receivables and Allowance for Doubtful Accounts
	The Company, through its subsidiary LCA-Vision, provides financing to some of its patients, including those who could not otherwise obtain third-party financing. The terms of the financing usually require the patient to pay an up-front fee which is intended to cover some or all of the variable costs, and then generally the remainder of the payments are automatically deducted from the patient’s bank account over a period of 12 to 36 months. The Company has recorded an allowance for doubtful accounts as a best estimate of the amount of probable credit losses from the patient financing program. Each month, management reviews and adjusts the allowance based upon past experience with patient financing. The Company charges-off receivables against the allowance for doubtful accounts when it is probable that a receivable will not be recovered. The Company’s policy is to reserve for all patient receivables that remain open past their financial maturity date and to provide reserves for patient collectability rates, recent default activity and the current credit environment. Bad debt expense, on patient receivables, was $111 or less than 1% of the clinics revenues for the period of May 13, 2014 through June 30, 2014.
	For patients that the Company internally finance, the Company charges interest at market rates. Finance and interest charges on patient receivables were $113 for the periods ended June 30, 2014.
Insurance Reserves	'
	Insurance Reserves
	The Company, through its subsidiary LCA-Vision, maintains a captive insurance company to provide professional liability insurance coverage for claims brought against the Company and its optometrists. In addition, the captive insurance company’s charter allows it to provide professional liability insurance for the Company’s ophthalmologists, none of whom are currently insured by the captive. The Company uses the captive insurance company for both primary insurance and excess liability coverage. A number of claims are now pending with the captive insurance company. Since the captive insurance company is wholly-owned enterprise so it is included in the Company’s consolidated financial statements. As of June 30, 2014, the insurance reserves were $6,111, which represented an actuarially determined estimate of future costs associated with claims filed as well as claims incurred but not yet reported. The actuaries determine loss reserves by comparing the Company’s historical claim experience to comparable insurance industry experience.
Functional Currency	'
	Functional Currency
	The currency of the primary economic environment in which the operations of the Company, its U.S. subsidiaries and Radiancy Ltd., its subsidiary in Israel, are conducted is the US dollar ("$" or "dollars"). Thus, the functional currency of the Company and its subsidiaries (other than the foreign subsidiaries mentioned below) is the dollar (which is also the reporting currency of the Group). The other foreign subsidiaries are each conducted in the local currency of the subsidiary. These currencies include: Great Britain Pounds (GBP), Brazilian Real (BRL), Hong Kong Dollar (HKD), Columbian Peso (COP) and Indian Rupee (INR). Substantially all of the Group's revenues are derived in dollars or in other currencies linked to the dollar. Purchases of most materials and components are carried out in, or linked to the dollar.
	Balances denominated in, or linked to, foreign currencies are stated on the basis of the exchange rates prevailing at the balance sheet date. For foreign currency transactions included in the statement of comprehensive income, the exchange rates applicable to the relevant transaction dates are used. Transaction gains or losses arising from changes in the exchange rates used in the translation of such balances are carried to financing income or expenses.
	Assets and liabilities of foreign subsidiaries, whose functional currency is their local currency, are translated from their respective functional currency to U.S. dollars at the balance sheet date exchange rates. Income and expense items are translated at the average rates of exchange prevailing during the year. Translation adjustments are reflected in the consolidated balance sheets as a component of accumulated other comprehensive income. Deferred taxes are not provided on translation adjustments as the earnings of the subsidiaries are considered to be permanently reinvested.
Fair Value Measurements	'
	Fair Value Measurements
	The Company measures and discloses fair value in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification 820, Fair Value Measurements and Disclosures (“ASC Topic 820”). ASC Topic 820 defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions there exists a three-tier fair-value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
		•	Level 1 – unadjusted quoted prices are available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.
		•	Level 2 – pricing inputs are other than quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data.
		•	Level 3 – pricing inputs are unobservable for the non-financial asset or liability and only used when there is little, if any, market activity for the non-financial asset or liability at the measurement date. The inputs into the determination of fair value require significant management judgment or estimation. Fair value is determined using comparable market transactions and other valuation methodologies, adjusted as appropriate for liquidity, credit, market and/or other risk factors
	This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.
	The fair value of cash and cash equivalents and short term bank deposits are based on its demand value, which is equal to its carrying value. The estimated fair values of notes payable which are based on borrowing rates that are available to the Company for loans with similar terms, collateral and maturity approximate the carrying values. Additionally, the carrying value of all other monetary assets (including long term receivables which bear interest) and liabilities is estimated to be equal to their fair value due to the short-term nature or commercial terms of these instruments.
	Derivative financial instruments are measured at fair value, on a recurring basis. The fair value of derivatives generally reflects the estimated amounts that the Group would receive or pay to terminate the contracts at the reporting dates, based on the prevailing currency prices and the relevant interest rates. Such measurement is classified within Level 2.
	In addition to items that are measured at fair value on a recurring basis, there are also assets and liabilities that are measured at fair value on a nonrecurring basis. Assets and liabilities that are measured at fair value on a nonrecurring basis include certain long-lived assets including goodwill. As such, we have determined that each of these fair value measurements reside within Level 3 of the fair value hierarchy.
Derivatives	'
	Derivatives
	The group applies the provisions of Accounting Standards Codification ("ASC") Topic 815, Derivatives and Hedging. In accordance with ASC Topic 815, all the derivative financial instruments are recognized as either financial assets or financial liabilities on the balance sheet at fair value. The accounting for changes in the fair value of a derivative financial instrument depends on whether it has been designated and qualifies as part of a hedging relationship and further, on the type of hedging relationship. For derivative financial instruments that are designated and qualify as hedging instruments, a company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, cash flow hedge or a hedge of a net investment in a foreign operation.
	From time to time the Company carries out transactions involving foreign exchange derivative financial instruments (mainly forward exchange contracts) which are designed to hedge the cash flows expected to be paid with respect to forecasted expenses of the Israeli subsidiary (Radiancy) denominated in Israeli local currency (NIS) which is different than its functional currency.
	Such derivatives were not designated as hedging instruments, and accordingly they were recognized in the balance sheet at their fair value, with changes in the fair value carried to the Statement of Comprehensive Income and included in financing income (expenses), net.
	At June 30, 2014, the balance of such derivative instruments amounted to approximately $118 in assets and approximately $93 and $183 were recognized as financing income in the Statement of Comprehensive Income during the three and six months ended June 30, 2014, respectively.
	The nominal amounts of foreign currency derivatives as of June 30, 2014 consist of forward transactions for the exchange of $5,200 into NIS as of June 30, 2014.
Accrued Enhancement Expense	'
	Accrued Enhancement Expense
	The Company, through its subsidiary LCA-Vision, includes participation in its LasikPlus Advantage Plan® (acuity program) in the base surgical price for substantially all of its patients. Under the acuity program, if determined to be medically appropriate, the Company provides post-surgical enhancements free of charge should the patient not achieve the desired visual correction during the initial procedure. Under this pricing structure, the Company accounts for the acuity program similar to a warranty obligation. Accordingly, the Company accrues the costs expected to be incurred to satisfy the obligation as a liability and cost of revenue at the point of sale given its ability to estimate reasonably such costs based on historical trends and the satisfaction of all other revenue recognition criteria.
	This estimate is reviewed throughout the year with consideration to factors such as procedure cost and historical procedure volume when determining the appropriateness of the recorded balance.
Accrued Warranty Costs	'
	Accrued Warranty Costs
	The Company offers a standard warranty on product sales generally for a one to two-year period. In the case of domestic sales of XTRAC lasers, however, the Company has offered longer warranty periods, ranging from three to four years, in order to meet competition or meet customer demands. The Company provides for the estimated cost of the future warranty claims on the date the product is sold. Total accrued warranty is included in Other Accrued Liabilities on the balance sheet. The activity in the warranty accrual during the six months ended June 30, 2014 and 2013 is summarized as follows:
			June 30,
			2014			2013
			(unaudited)			(unaudited)
	Accrual at beginning of year		$	1,151		$	1,440
	Additions charged to warranty expense			398			691
	Expiring warranties			(116	)		(281	)
	Claims satisfied			(497	)		(655	)
	Total			936			1,195
	Less: current portion			(864	)		(1,117	)
	Accrued extended warranty		$	72		$	78
	For extended warranty on the consumer products, see Revenue Recognition above.
Earnings Per Share	'
	Earnings Per Share
	Basic and diluted earnings per common share were calculated using the following weighted-average shares outstanding:
			For the Three Months Ended June 30,			For the Six Months Ended
						June 30,
			2014		2013		2014		2013
	Weighted-average number of common and common equivalent shares outstanding:
	Basic number of common shares outstanding		18,723,484		20,573,048		18,721,463		20,624,588
	Dilutive effect of stock options and warrants		-		460,301		-		460,301
	Diluted number of common and common stock equivalent shares outstanding		18,723,484		21,033,349		18,721,463		21,084,889
	Diluted earnings per share for the three and six months ended June 30, 2014, exclude the impact of common stock options and warrants, totaling 2,550,516 shares, as the effect of their inclusion would be anti-dilutive. Diluted earnings per share for the three and six months ended June 30, 2013, excluded the impact of common stock options and warrants, totaling 2,200,350 shares, as the effect of their inclusion would be anti-dilutive.
Adoption of New Accounting Standards	'
	Adoption of New Accounting Standards
	Effective January 1, 2014, the Company adopted Accounting Standard Update 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force) ("ASU 2013-11").
	The amendments in ASU 2013-11 state that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, except as follows: To the extent a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be presented net of deferred tax assets.
	ASU 2013-11 applies to all entities that have unrecognized tax benefits when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists at the reporting date. For public companies the amendments in this ASU became effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments were applied prospectively to all unrecognized tax benefits that existed at the effective date.
	The adoption of the standard did not have a material impact on the Company's consolidated results of operations and financial condition.
	Effective January 1, 2014, the Company adopted Accounting Standards Update 2013-5, Foreign Currency Matters (Topic 830) Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity ("ASU 2013-5").
	ASU 2013-5 clarifies that, when a reporting entity (parent) ceases to have a controlling financial interest in a subsidiary or group of assets that is a business (other than a sale of in-substance real estate or conveyance of oil and gas mineral rights) within a foreign entity, the parent is required to apply the guidance in Subtopic 830-30 to release any related cumulative translation adjustment into net income. Accordingly, the cumulative translation adjustment should be released into net income only if the sale or transfer results in the complete or substantially complete liquidation of the foreign entity in which the subsidiary or group of assets had resided. ASU 2013-5 also clarifies that if the business combination achieved in stages relates to a previously held equity method investment (step-acquisition) that is a foreign entity, the amount of accumulated other comprehensive income that is reclassified and included in the calculation of gain or loss shall include any foreign currency translation adjustment related to that previously held investment.
	For public companies, the amendments in this Update became effective prospectively for fiscal years (and interim reporting periods within those years) beginning after December 15, 2013. In accordance with the transition requirements, the amendments should be applied prospectively to derecognition events occurring after the effective date. Prior periods should not be adjusted.
	The adoption of the standard did not have a material impact on the Company's consolidated results of operations and financial condition.

The_Company_Tables

The Company (Tables)	6 Months Ended
	Jun. 30, 2014
The Company [Abstract]	'
Activity in the Warranty Accrual	'
	The activity in the warranty accrual during the six months ended June 30, 2014 and 2013 is summarized as follows:
		June 30,
		2014			2013
		(unaudited)			(unaudited)
	Accrual at beginning of year	$	1,151		$	1,440
	Additions charged to warranty expense		398			691
	Expiring warranties		(116	)		(281	)
	Claims satisfied		(497	)		(655	)
	Total		936			1,195
	Less: current portion		(864	)		(1,117	)
	Accrued extended warranty	$	72		$	78
Calculation of Basic and Diluted Earnings per Common Share	'
	Basic and diluted earnings per common share were calculated using the following weighted-average shares outstanding:
		For the Three Months Ended June 30,			For the Six Months Ended
					June 30,
		2014		2013		2014		2013
	Weighted-average number of common and common equivalent shares outstanding:
	Basic number of common shares outstanding	18,723,484		20,573,048		18,721,463		20,624,588
	Dilutive effect of stock options and warrants	-		460,301		-		460,301
	Diluted number of common and common stock equivalent shares outstanding	18,723,484		21,033,349		18,721,463		21,084,889

Acquisition_of_LCAVision_Inc_T

Acquisition of LCA-Vision Inc (Tables)	6 Months Ended
	Jun. 30, 2014
Acquisition of LCA-Vision Inc [Abstract]	'
Schedule of Aggregate Consideration Paid	'
	The fair value of the assets acquired and liabilities assumed were based on management estimates and values derived from an outside independent appraisal. The Company expects that the allocation will be finalized within twelve months after the merger. Based on the purchase price allocation, the following table summarizes the estimated provisional fair value amounts of the assets acquired and liabilities assumed at the date of acquisition:
	Cash and cash equivalents	$	29,042
	Current assets, excluding cash and cash equivalents		6,114
	Deferred tax asset, current		1,124
	Property, plant and equipment		17,269
	Identifiable intangible assets		39,050
	Other assets		1,518
	Total assets acquired at fair value		94,117
	Current liabilities		(19,009	)
	Long-term debt		(1,603	)
	Deferred tax liability, long-term		(9,138	)
	Other long-term liabilities		(7,397	)
	Total liabilities assumed		(37,147	)
	Net assets acquired	$	56,970
Purchase Price Allocation	'
	The purchase price of LCA-Vision was $106,552 in aggregate consideration, paid in cash (including the full use of the credit facility), consisting of:
	Fair value LCA-Vision stock (A)	$	103,896
	Fair value of LCA-Vision restricted stock units, including payroll taxes (B)		2,656
	Total purchase price	$	106,552
Pro Forma Information	'
	The consolidated results of operations do not include any revenues or expenses related to the LCA-Vision business on or prior to May 13, 2014, the consummation date of the acquisition. The Company’s unaudited pro-forma results for the three and six months ended June 30, 2014 and 2014 summarize the combined results of PhotoMedex and LCA-Vision in the following table, assuming the acquisition had occurred on January 1, 2013 and after giving effect to the acquisition adjustments, including amortization of the tangible and definite-lived intangible assets were acquired in the transaction:
		Three Months Ended June 30,					Six Months Ended June 30,
		2014			2013		2014			2013
		(unaudited)			(unaudited)		(unaudited)			(unaudited)
	Net revenues	$	61,170		$	80,674	$	136,776		$	166,194
	Net income (loss)		(14,734	)		5,762		(16,747	)		12,579
	Net income (loss) per share:
	Basic	$	(0.79	)	$	0.28	$	(0.89	)	$	0.61
	Diluted	$	(0.79	)	$	0.27	$	(0.89	)	$	0.6
	Shares used in calculating net income (loss) per share:
	Basic		18,723,484			20,573,048		18,721,463			20,624,588
	Diluted		18,723,484			21,033,349		18,721,463			21,084,889

Inventories_net_Tables

Inventories, net (Tables)	6 Months Ended
	Jun. 30, 2014
Inventories, net [Abstract]	'
Inventories, net	'
	Inventories, net:
		30-Jun-14		31-Dec-13
		(unaudited)
	Raw materials and work in progress	$	10,252	$	12,631
	Finished goods		15,366		14,916
	Total inventories, net	$	25,618	$	27,547

Property_and_Equipment_net_Tab

Property and Equipment, net (Tables)	6 Months Ended
	Jun. 30, 2014
Property and Equipment, net [Abstract]	'
Property and Equipment, net	'
	Property and Equipment, net:
		30-Jun-14			31-Dec-13
		(unaudited)
	Lasers-in-service	$	23,540		$	12,599
	Equipment, computer hardware and software		5,725			4,730
	Furniture and fixtures		1,343			705
	Land and building		2,905			-
	Leasehold improvements		5,725			534
			39,238			18,568
	Accumulated depreciation and amortization		(10,100	)		(8,079	)
	Property and equipment, net	$	29,138		$	10,489

Patents_and_Licensed_Technolog1

Patents and Licensed Technologies, net (Tables)	6 Months Ended
	Jun. 30, 2014
Patents and Licensed Technologies, net [Abstract]	'
Patents and Licensed Technologies	'
	Patents and Licensed Technologies, net:
		30-Jun-14			31-Dec-13
		(unaudited)
	Gross Amount beginning of period	$	15,648		$	15,411
	Additions		98			171
	Translation differences		107			66
	Gross Amount end of period		15,853			15,648
	Accumulated amortization		(5,893	)		(4,816	)
	Patents and licensed technologies, net	$	9,960		$	10,832
Amortization Expense for Amortizable Patents and Licensed Technologies	'
	Estimated amortization expense for amortizable patents and licensed technologies assets for the next five years is as follows:
	Last six months of 2014	$	1,062
	2015		2,049
	2016		2,059
	2017		909
	2018		899
	Thereafter		2,982
	Total	$	9,960

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets, net (Tables)	6 Months Ended
	Jun. 30, 2014
Goodwill and Other Intangible Assets, net [Abstract]	'
Goodwill Acquired	'
	The purchase price intrinsically recognizes the benefits of leveraging under-utilized clinics by establishing XTRAC centers of excellence in key markets.
		Goodwill			Trademarks
	Balance at January 1, 2014	$	24,930		$	-
	Additions for LCA-Vision acquisition		49,582			29,850
	Translation differences		498			-
	Balance at June 30, 2014	$	75,010		$	29,850
Other Definite-lived Intangible Assets	'
	Set forth below is a detailed listing of other definite-lived intangible assets:
		30-Jun-14
		(unaudited)
		Trademarks			Customer Relationships			Managed Care Network			Total
	Gross Amount beginning of period	$	5,772		$	6,417		$	-		$	12,189
	Additions		-			-			9,200			9,200
	Translation differences		46			72			-			118
	Gross Amount end of period		5,818			6,489			9,200			21,507
	Accumulated amortization		(1,479	)		(1,649	)		(144	)		(3,272	)
	Net Book Value	$	4,339		$	4,840		$	9,056		$	18,235
		31-Dec-13
		Trademarks			Customer Relationships			Managed Care Network			Total
	Gross Amount beginning of period	$	5,744		$	6,372		$	-		$	12,116
	Translation differences		28			45			-			73
	Gross Amount end of period		5772			6,417			-			12,189
	Accumulated amortization		(1,178	)		(1,310	)		-			(2,488	)
	Net Book Value	$	4,594		$	5,107		$	-		$	9,701
Estimated Amortization Expense for Amortizable Intangible Assets	'
	Estimated amortization expense for the above amortizable intangible assets for the next five years is as follows:
	Last six months of 2014	$	1,175
	2015		2,350
	2016		2,350
	2017		2,350
	2018		2,350
	Thereafter		7,660
	Total	$	18,235

Accrued_Compensation_and_relat1

Accrued Compensation and related expenses (Tables)	6 Months Ended
	Jun. 30, 2014
Accrued Compensation and related expenses [Abstract]	'
Accrued Compensation and Related Expenses	'
	Accrued Compensation and related expenses:
		30-Jun-14		31-Dec-13
		(unaudited)
	Accrued payroll and related taxes	$	1,932	$	707
	Accrued vacation		442		290
	Accrued commissions and bonus		1,600		2,233
	Total accrued compensation and related expense	$	3,974	$	3,230

Other_Accrued_Liabilities_Tabl

Other Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2014
Other Accrued Liabilities [Abstract]	'
Other Accrued Liabilities	'
	Other Accrued Liabilities:
			30-Jun-14			31-Dec-13
			(unaudited)
	Accrued warranty, current, see Note 1		$	864		$	1,094
	Accrued taxes, net			1,753			1,023
	Accrued sales returns (1)			6,547			16,046
	Insurance liability reserves, current			805			-
	Accrued enhancement expenses, current			836			-
	Other accrued liabilities			5,162			3,869
	Total other accrued liabilities		$	15,967		$	22,032
	(1)	The activity in the sales returns liability account was as follows:
			Six Months Ended June 30,
			2014			2013
			(unaudited)			(unaudited)
	Balance at beginning of year		$	16,046		$	11,901
	Additions that reduce net sales			18,636			17,156
	Deductions from reserves			(28,135	)		(21,117	)
	Balance at end of period		$	6,547		$	7,940

LongTerm_Other_Liabilities_Tab

Long-Term Other Liabilities (Tables)	6 Months Ended
	Jun. 30, 2014
Long-Term Other Liabilities [Abstract]	'
Other Long-Term Liabilities	'
	Long-Term Other Liabilities:
		30-Jun-14		31-Dec-13
		(unaudited)
	Long-term insurance liability reserves, net of current portion	$	5,305	$	-
	Accrued enhancement expenses, net of current portion		1,140		-
	Other liabilities		834		61
	Total long-term liabilities	$	7,279	$	61

Longterm_Debt_Tables

Long-term Debt (Tables)	6 Months Ended
	Jun. 30, 2014
Long-term Debt [Abstract]	'
Schedule of Long-term Debt	'
	In the following table is a summary of the Company’s long-term debt:
		30-Jun-14			31-Dec-13
		(unaudited)
	Senior-secured credit facilities, net of unamortized debt discount of $606	$	84,394		$	-
	Term note		-			10,000
	Third-party debt		1,472			-
	Sub-total		85,866			10,000
	Less: current portion		85,185			10,000
	Long-term debt	$	681		$	-
Maturities of Long-term Debt	'
	The following table summarizes the future minimum payments that the Company expects to make for long-term debt:
	Last six months of 2014	$	7,892
	2015		17,405
	2016		19,025
	2017		20,900
	2018		21,250
	Total minimum payments		86,472
	Less: unamortized discount		(606	)
	Present value of total minimum obligations	$	85,866

Employee_Stock_Benefit_Plans_T

Employee Stock Benefit Plans (Tables)	6 Months Ended
	Jun. 30, 2014
Employee Stock Benefit Plans [Abstract]	'
Stock Option Activity	'
	Stock option activity under all of the Company’s share-based compensation plans for the six months ended June 30, 2014 was as follows:
			Number of			Weighted Average Exercise Price
			Options
	Outstanding, January 1, 2014			1,132,678		$	16.51
	Granted			180,500			14.11
	Exercised			-			-
	Cancelled			(4,999	)		58.63
	Outstanding, June 30, 2014			1,308,179		$	16.02
	Options exercisable at June 30, 2014			517,179		$	16.45
Weighted Average Assumptions Used to Estimate Fair Value of Stock Options	'
	The Company uses the Black-Scholes option-pricing model to estimate fair value of grants of stock options with the following weighted-average assumptions:
		Three Months Ended June 30, 2014		Six Months Ended June 30, 2014
	Risk-free interest rate	2.21%		2.17%
	Volatility	76.61%		78.41%
	Expected dividend yield	0%		0%
	Expected life	5.5 years		5.5 years
	Estimated forfeiture rate	0%		0%

Business_Segments_and_Geograph1

Business Segments and Geographic Data (Tables)	6 Months Ended
	Jun. 30, 2014
Business Segments and Geographic Data [Abstract]	'
Results of Operations from Business Segments	'
	The following tables reflect results of operations from our business segments for the periods indicated below:
	Three Months Ended June 30, 2014 (unaudited)
		Consumer			Physician Recurring			Professional			Clinics			Total
	Revenues	$	28,453		$	8,607		$	1,917		$	13,143		$	52,120
	Costs of revenues		3,983			3,425			1,361			8,883			17,652
	Gross profit		24,470			5,182			556			4,260			34,468
	Gross profit %		86	%		60.2	%		29	%		32.4	%		66.1	%
	Allocated operating expenses:
	Engineering and product development		305			257			161			-			723
	Selling and marketing expenses		23,223			4,268			274			2,655			30,420
	Unallocated operating expenses		-			-			-			-			11,452
			23,528			4,525			435			2,655			42,595
	Income (loss) from operations		942			657			121			1,605			(8,127	)
	Interest  and other financing expense, net		-			-			-			-			(175	)
	Net income (loss) before taxes	$	942		$	657		$	121		$	1,605		$	( 8,302	)
	Three Months Ended June 30, 2013 (unaudited)
		Consumer			Physician Recurring			Professional			Clinics			Total
	Revenues	$	48,673		$	7,376		$	2,016		$	-		$	58,065
	Costs of revenues		7,174			3,014			1,202			-			11,390
	Gross profit		41,499			4,362			814			-			46,675
	Gross profit %		85.3	%		59.1	%		40.4	%		N/A			80.4	%
	Allocated operating expenses:
	Engineering and product development		279			317			218			-			814
	Selling and marketing expenses		26,703			3,233			532			-			30,468
	Unallocated operating expenses		-			-			-			-			6,268
			26,982			3,550			750			-			37,550
	Income from operations		14,517			812			64			-			9,125
	Interest and other financing expense, net		-			-			-			-			(134	)
	Net income before taxes	$	14,517		$	812		$	64		$	-		$	8,991
	Six Months Ended June 30, 2014 (unaudited)
		Consumer			Physician Recurring			Professional			Clinics			Total
	Revenues	$	69,323		$	15,826		$	3,903		$	13,143		$	102,195
	Costs of revenues		10,233			6,255			2,626			8,883			27,997
	Gross profit		59,090			9,571			1,277			4,260			74,198
	Gross profit %		85.2	%		60.5	%		32.7	%		32.4	%		72.6	%
	Allocated operating expenses:
	Engineering and product development		592			567			359			-			1,518
	Selling and marketing expenses		50,381			8,279			731			2,655			62,046
	Unallocated operating expenses		-			-			-			-			19,039
			50,973			8,846			1,090			2,655			82,603
	Income from operations		8,117			725			187			1,605			(8,405	)
	Interest and other financing expense, net		-			-			-			-			(321	)
	Net income (loss)before taxes	$	8,117		$	725		$	187		$	1,605		$	(8,726	)
	Six Months Ended June 30, 2013 (unaudited)
		Consumer			Physician Recurring			Professional			Clinics			Total
	Revenues	$	97,733			13,331		$	4,217		$	-		$	115,281
	Costs of revenues		14,691			5,945			2,620			-			23,256
	Gross profit		83,042			7,386			1,597			-			92,025
	Gross profit %		85	%		55.4	%		37.9	%		N/A			79.8	%
	Allocated operating expenses:
	Engineering and product development		497			641			449			-			1,587
	Selling and marketing expenses		52,334			6,407			1,053			-			59,794
	Unallocated operating expenses		-			-			-			-			11,927
			52,831			7,048			1,502			-			73,308
	Income from operations		30,211			338			95			-			18,717
	Interest  and other financing expense, net		-			-			-			-			(3	)
	Net income before taxes	$	30,211		$	338		$	95		$	-		$	18,714
Net Revenues and Long-Lived Assets by Geographical Area	'
	For the three and six months ended June 30, 2014 and 2013 (unaudited), net revenues by geographic area were as follows:
		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2014			2013			2014			2013
	North America 1	$	41,803		$	42,033		$	81,776		$	86,932
	Asia Pacific 2		2,638			9,440			5,015			15,202
	Europe (including Israel)		7,084			5,861			14,492			11,494
	South America		595			731			912			1,653
		$	52,120		$	58,065		$	102,195		$	115,281
	1 United States	$	38,612		$	37,329		$	73,379		$	75,336
	1 Canada	$	3,191		$	4,704		$	8,397		$	11,596
	2  Japan	$	290		$	7,452		$	988		$	11,715
	As of June 30, 2014 and December 31, 2013, long-lived assets by geographic area were as follows:
		30-Jun-14			31-Dec-13
		(unaudited)
	North America	$	27,859		$	9,119
	Asia Pacific		4			-
	Europe (including Israel)		1,270			1,370
	South America		5			-
		$	29,138		$	10,489

Significant_Customer_Concentra1

Significant Customer Concentration (Tables)	6 Months Ended
	Jun. 30, 2014
Significant Customer Concentration [Abstract]	'
Significant Customer Concentration	'
	No customer was more than 10% of total company revenues for the three and six months ended June 30, 2014. For the three and six months ended June 30, 2013, there were two customers more than 10% of revenues.
		Three Months Ended June 30, 2013	Six Months Ended June 30, 2013
	Customer A	11%	11%
	Customer B	12%	9%

The_Company_Details

The Company (Details) (USD $)

3 Months Ended

6 Months Ended

6 Months Ended

6 Months Ended

6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Jun. 30, 2014

12-May-14

Jun. 30, 2014

12-May-14

Jun. 30, 2014

12-May-14

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Segment

Senior-Secured Credit Facilities [Member]

Senior-Secured Credit Facilities [Member]

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

Term Loan [Member]

Term Loan [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

PhotoMedex, Inc. [Member]

Radiancy, Inc. [Member]

LCA Vision Inc [Member]

Senior-Secured Credit Facilities [Member]

Senior-Secured Credit Facilities [Member]

Eurodollar [Member]

Eurodollar [Member]

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum borrowing capacity

'

'

'

'

'

$85,000,000

$85,000,000

$10,000,000

$10,000,000

$75,000,000

$75,000,000

'

'

'

'

'

'

'

Term loan period

'

'

'

'

'

'

'

'

'

'4 years

'

'

'

'

'

'

'

'

Effective interest rate (in hundredths)

'

'

'

'

'

'

'

'

'

'

'

'

3.25%

'

4.50%

'

'

'

Possible increase in interest (in hundredths)

'

'

'

'

'

2.00%

'

'

'

'

'

'

'

'

'

'

'

'

Effective date of merger

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12-May-14

Percentage of ownership on reverse merger (in hundredths)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20.00%

80.00%

'

Number of operating units

'

'

4

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of shares acquired by wholly-owned subsidiary (in hundredths)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100.00%

Revenue Recognition [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of distribution channels

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Period of sales deferred

'

'

'14 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Patient Receivables and Allowance for Doubtful Accounts [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Minimum collection period of patient receivables

'

'

'12 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum collection period of patient receivables

'

'

'36 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Bad debt expense, on patient receivables

'

'

111,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of bad debt expenses on patient receivables (in hundredths)

'

'

1.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Finance and interest charges on patient receivables

'

'

113,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Insurance Reserves [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Insurance reserves

6,111,000

'

6,111,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivatives [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance of derivative instruments

118,000

'

118,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount recognized as financing income

93,000

'

183,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Notional amounts of foreign currency derivatives

5,200,000

'

5,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warranty on Product Sales [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Period of warranty on product sales

'

'

'

'

'

'

'

'

'

'

'

'1 year

'

'2 years

'

'

'

'

Extended period of warranty on domestic sale of laser equipment

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

'4 years

'

'

'

'

Activity in warranty accrual [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrual at beginning of year

'

'

1,151,000

1,440,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additions charged to warranty expense

'

'

398,000

691,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expiring warranties

'

'

-116,000

-281,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Claims satisfied

'

'

-497,000

-655,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total

936,000

1,195,000

936,000

1,195,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Less: current portion

-864,000

-1,117,000

-864,000

-1,117,000

-1,094,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued long-term warranty

$72,000

$78,000

$72,000

$78,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted-average number of common and common equivalent shares outstanding [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Basic number of common shares outstanding (in shares)

18,723,484

20,573,048

18,721,463

20,624,588

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Dilutive effect of stock options and warrants (in shares)

0

460,301

0

460,301

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Diluted number of common and common stock equivalent shares outstanding (in shares)

18,723,484

21,033,349

18,721,463

21,084,889

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock options and warrants excluded from computation of diluted earnings per share (in shares)

2,550,516

2,200,350

2,550,516

2,200,350

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Acquisition_of_LCAVision_Inc_D

Acquisition of LCA-Vision Inc (Details) (USD $)	3 Months Ended		6 Months Ended			3 Months Ended		6 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Jun. 30, 2014		Jun. 30, 2014	12-May-14
						LCA Vision Inc [Member]		LCA Vision Inc [Member]	LCA Vision Inc [Member]
Business Acquisition [Line Items]	'	'	'	'	'	'		'	'
Effective date of merger	'	'	'	'	'	'		12-May-14	'
Percentage of shares acquired by wholly-owned subsidiary (in hundredths)	'	'	'	'	'	'		'	100.00%
Fair value LCA-Vision stock	'	'	'	'	'	$103,896	[1]	'	'
Fair value of LCA-Vision restricted stock units, including payroll taxes	'	'	'	'	'	2,656	[2]	'	'
Total purchase price	'	'	'	'	'	106,552		'	'
Common Stock, outstanding (in shares)	19,049,582	'	19,049,582	'	18,903,245	'		'	19,347,554
Restricted stock, outstanding or deemed to be outstanding (in shares)	'	'	'	'	'	'		'	476,436
Goodwill	75,010	'	75,010	'	24,930	'		'	49,582
Fair value of the assets acquired and liabilities assumed [Abstract]	'	'	'	'	'	'		'	'
Cash and cash equivalents	'	'	'	'	'	'		'	29,042
Current assets, excluding cash and cash equivalents	'	'	'	'	'	'		'	6,114
Deferred tax asset, current	'	'	'	'	'	'		'	1,124
Property, plant and equipment	'	'	'	'	'	'		'	17,269
Identifiable intangible assets	'	'	'	'	'	'		'	39,050
Other assets	'	'	'	'	'	'		'	1,518
Total assets acquired at fair value	'	'	'	'	'	'		'	94,117
Current liabilities	'	'	'	'	'	'		'	-19,009
Long-term debt	'	'	'	'	'	'		'	-1,603
Deferred tax liability, long-term	'	'	'	'	'	'		'	-9,138
Other long-term liabilities	'	'	'	'	'	'		'	-7,397
Total liabilities assumed	'	'	'	'	'	'		'	-37,147
Net assets acquired	'	'	'	'	'	'		'	56,970
Summarized combined result after giving effect acquisition adjustments [Abstract]	'	'	'	'	'	'		'	'
Net revenues	61,170	80,674	136,776	166,194	'	'		'	'
Net income (loss)	($14,734)	$5,762	($16,747)	$12,579	'	'		'	'
Net income (loss) per share: [Abstract]	'	'	'	'	'	'		'	'
Basic (in dollars per share)	($0.79)	$0.28	($0.89)	$0.61	'	'		'	'
Diluted (in dollars per share)	($0.79)	$0.27	($0.89)	$0.60	'	'		'	'
Shares used in calculating net income (loss) per share [Abstract]	'	'	'	'	'	'		'	'
Basic (in shares)	18,723,484	20,573,048	18,721,463	20,624,588	'	'		'	'
Diluted (in shares)	18,723,484	21,033,349	18,721,463	21,084,889	'	'		'	'
[1]	Based on 19,347,554 outstanding shares of LCA-Vision common stock at May 12, 2014.
[2]	Based on 476,436 outstanding or deemed to be outstanding restricted stock units of LCA-Vision common stock at May 12, 2014.

Inventories_net_Details

Inventories, net (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Schedule of inventories [Abstract]	'	'
Raw materials and work-in-process	$10,252	$12,631
Finished goods	15,366	14,916
Total inventories, net	$25,618	$27,547

Property_and_Equipment_net_Det

Property and Equipment, net (Details) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Schedule property and equipment [Abstract]	'	'	'
Property and equipment, gross	$39,238	'	$18,568
Accumulated depreciation and amortization	-10,100	'	-8,079
Total property and equipment, net	29,138	'	10,489
Depreciation and related amortization expense	2,390	1,343	'
Lasers-in-Service [Member]	'	'	'
Schedule property and equipment [Abstract]	'	'	'
Property and equipment, gross	23,540	'	12,599
Equipment, Computer Hardware and Software [Member]	'	'	'
Schedule property and equipment [Abstract]	'	'	'
Property and equipment, gross	5,725	'	4,730
Furniture and Fixtures [Member]	'	'	'
Schedule property and equipment [Abstract]	'	'	'
Property and equipment, gross	1,343	'	705
Land and Building [Member]	'	'	'
Schedule property and equipment [Abstract]	'	'	'
Property and equipment, gross	2,905	'	0
Leasehold Improvements [Member]	'	'	'
Schedule property and equipment [Abstract]	'	'	'
Property and equipment, gross	$5,725	'	$534

Patents_and_Licensed_Technolog2

Patents and Licensed Technologies, net (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2014	Jun. 30, 2013
In Thousands, unless otherwise specified			Patents and Licensed Technologies [Member]	Patents and Licensed Technologies [Member]
Patents and Licensed Technologies [Abstract]	'	'	'	'
Gross Amount beginning of period	'	'	$15,648	$15,411
Additions	'	'	98	171
Translation differences	'	'	107	66
Gross Amount end of period	'	'	15,853	15,648
Accumulated amortization	'	'	-5,893	-4,816
Patents and licensed technologies, net	9,960	10,832	9,960	10,832
Amortization expense	'	'	1,040	1,020
Estimated amortization expense for amortizable patents and licensed technologies assets [Abstract]	'	'	'	'
Last six months of 2014	'	'	1,062	'
2015	'	'	2,049	'
2016	'	'	2,059	'
2017	'	'	909	'
2018	'	'	899	'
Thereafter	'	'	2,982	'
Patents and licensed technologies, net	$9,960	$10,832	$9,960	$10,832

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets, net (Details) (USD $)	3 Months Ended		6 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Dec. 31, 2013
Goodwill [Roll Forward]	'	'	'	'
Goodwill, beginning balance	'	'	$24,930	'
Goodwill, ending balance	75,010	'	75,010	24,930
Definite-lived intangibles	48,085	'	48,085	9,701
Schedule of definite-lived intangible assets [Abstract]	'	'	'	'
Gross Amount beginning of period	'	'	12,189	12,116
Additions	'	'	9,200	'
Translation differences	'	'	118	73
Gross Amount end of period	21,507	'	21,507	12,189
Accumulated amortization	-3,272	'	-3,272	-2,488
Net Book Value	18,235	'	18,235	9,701
Amortization expense	756	600	'	'
Estimated amortization expense for amortizable intangible assets [Abstract]	'	'	'	'
Last six months of 2014	1,175	'	1,175	'
2015	2,350	'	2,350	'
2016	2,350	'	2,350	'
2017	2,350	'	2,350	'
2018	2,350	'	2,350	'
Thereafter	7,660	'	7,660	'
Net Book Value	18,235	'	18,235	9,701
Trademarks [Member]	'	'	'	'
Schedule of definite-lived intangible assets [Abstract]	'	'	'	'
Gross Amount beginning of period	'	'	5,772	5,744
Additions	'	'	0	'
Translation differences	'	'	46	28
Gross Amount end of period	5,818	'	5,818	5,772
Accumulated amortization	-1,479	'	-1,479	-1,178
Net Book Value	4,339	'	4,339	4,594
Estimated amortization expense for amortizable intangible assets [Abstract]	'	'	'	'
Net Book Value	4,339	'	4,339	4,594
Customer Relationships [Member]	'	'	'	'
Schedule of definite-lived intangible assets [Abstract]	'	'	'	'
Gross Amount beginning of period	'	'	6,417	6,372
Additions	'	'	0	'
Translation differences	'	'	72	45
Gross Amount end of period	6,489	'	6,489	6,417
Accumulated amortization	-1,649	'	-1,649	-1,310
Net Book Value	4,840	'	4,840	5,107
Estimated amortization expense for amortizable intangible assets [Abstract]	'	'	'	'
Net Book Value	4,840	'	4,840	5,107
Managed Care Network [Member]	'	'	'	'
Schedule of definite-lived intangible assets [Abstract]	'	'	'	'
Gross Amount beginning of period	'	'	0	0
Additions	'	'	9,200	'
Translation differences	'	'	0	0
Gross Amount end of period	9,200	'	9,200	0
Accumulated amortization	-144	'	-144	0
Net Book Value	9,056	'	9,056	0
Amortization Life	'	'	'10 years	'
Estimated amortization expense for amortizable intangible assets [Abstract]	'	'	'	'
Net Book Value	9,056	'	9,056	0
Radiancy, Inc. [Member]	'	'	'	'
Goodwill [Roll Forward]	'	'	'	'
Goodwill, ending balance	24,005	'	24,005	'
Definite-lived intangibles	12,000	'	12,000	'
Goodwill [Member]	'	'	'	'
Goodwill [Roll Forward]	'	'	'	'
Goodwill, beginning balance	'	'	24,930	'
Additions for LCA-Vision acquisition	'	'	49,582	'
Translation differences	'	'	498	'
Goodwill, ending balance	75,010	'	75,010	'
Trademarks [Member]	'	'	'	'
Goodwill [Roll Forward]	'	'	'	'
Goodwill, beginning balance	'	'	0	'
Additions for LCA-Vision acquisition	'	'	29,850	'
Translation differences	'	'	0	'
Goodwill, ending balance	$29,850	'	$29,850	'

Accrued_Compensation_and_relat2

Accrued Compensation and related expenses (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accrued Compensation and related expenses [Abstract]	'	'
Accrued payroll and related taxes	$1,932	$707
Accrued vacation	442	290
Accrued commissions and bonus	1,600	2,233
Total accrued compensation and related expense	$3,974	$3,230

Other_Accrued_Liabilities_Deta

Other Accrued Liabilities (Details) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Other Accrued Liabilities [Abstract]	'	'	'
Accrued warranty, current, see Note 1	$864	$1,117	$1,094
Accrued taxes, net	1,753	'	1,023
Accrued sales return	6,547	7,940	'
Insurance liability reserves, current	805	'	0
Accrued enhancement expenses, current	836	'	0
Other accrued liabilities	5,162	'	3,869
Total other accrued liabilities	15,967	'	22,032
Sales returns liability roll forward [Abstract]	'	'	'
Balance at beginning of year	16,046	11,901	'
Additions that reduce net sales	18,636	17,156	'
Deductions from reserves	-28,135	-21,117	'
Balance at end of period	$6,547	$7,940	'

LongTerm_Liabilities_Details

Long-Term Liabilities (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Long-Term Other Liabilities [Abstract]	'	'
Long-term insurance liability reserves, net of current portion	$5,305	$0
Accrued enhancement expenses, net of current portion	1,140	0
Other liabilities	834	61
Total long-term liabilities	$7,279	$61

Longterm_Debt_Details

Long-term Debt (Details) (USD $)

6 Months Ended

6 Months Ended

12 Months Ended

12 Months Ended

6 Months Ended

6 Months Ended

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

12-May-14

Dec. 31, 2013

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

12-May-14

Jun. 30, 2014

12-May-14

Jun. 30, 2014

Jun. 30, 2014

Senior-secured credit facilities [Member]

Senior-secured credit facilities [Member]

Senior-secured credit facilities [Member]

Term Note [Member]

Term Note [Member]

Term Note [Member]

Term Note [Member]

Third-party debt [Member]

Third-party debt [Member]

Revolving Credit Facility [Member]

Revolving Credit Facility [Member]

Term Loan [Member]

Term Loan [Member]

Minimum [Member]

Maximum [Member]

LIBOR [Member]

Federal [Member]

Senior-secured credit facilities [Member]

Senior-secured credit facilities [Member]

Eurodollar [Member]

Eurodollar [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sub-Total

$85,866,000

$10,000,000

$84,394,000

'

$0

$10,000,000

$0

'

'

$1,472,000

$0

'

'

'

'

'

'

Less: current portion

85,185,000

10,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long-term Debt

681,000

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum borrowing capacity

'

'

85,000,000

85,000,000

'

15,000,000

'

'

'

'

'

10,000,000

10,000,000

75,000,000

75,000,000

'

'

Total borrowings

'

'

'

'

'

'

'

'

10,000,000

'

'

'

'

'

'

'

'

Effective interest rate (in hundredths)

'

'

'

'

'

'

'

2.50%

0.50%

'

'

'

'

'

'

3.25%

4.50%

Possible increase in interest (in hundredths)

'

'

2.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Description of variable rate basis

'LIBOR plus 2.5%

'

'Eurodollar

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Repayment period (in years)

'

'

'4 years

'

'

'1 year

'

'

'

'36 months

'

'

'

'

'

'

'

Interest rate (in hundredths)

'

'

'

'

'

'

'

'

'

3.50%

'

'

'

'

'

'

'

Long-term Debt, Fiscal Year Maturity [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Last six months of 2014

7,892,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2015

17,405,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2016

19,025,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2017

20,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2018

21,250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total minimum payments

86,472,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Less: unamortized discount

-606,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sub-Total

$85,866,000

$10,000,000

$84,394,000

'

$0

$10,000,000

$0

'

'

$1,472,000

$0

'

'

'

'

'

'

Income_Taxes_Details

Income Taxes (Details)	3 Months Ended	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2014
Effective income tax rate reconciliation [Line Items]	'	'
Statutory income tax rate (in hundredths)	34.00%	34.00%
Israeli subsidiaries [Member] | Prospective [Member]	'	'
Effective income tax rate reconciliation [Line Items]	'	'
Preferred income tax rate ( in hundredths)	'	16.00%
Standard corporate income tax rate (in hundredths)	'	26.50%
UK Subsidiaries [Member]	'	'
Effective income tax rate reconciliation [Line Items]	'	'
Standard corporate income tax rate (in hundredths)	'	20.00%

Commitments_and_contingencies_

Commitments and contingencies (Details)	6 Months Ended			6 Months Ended
	Jun. 30, 2014	Jun. 30, 2014	Dec. 20, 2013	Jun. 30, 2014	Jun. 30, 2014
	USD ($)	ILS	State	Minimum [Member]	Maximum [Member]
	Lawsuit		Customer	USD ($)	USD ($)
	Executive
	Shareholder
Commitments and contingencies [Abstract]	'	'	'	'	'
Total operating lease obligations	$19,456,000	'	'	'	'
Operating lease obligation due in less than 1 year	5,910,000	'	'	'	'
Operating lease due between 1 to 3 years	9,149,000	'	'	'	'
Operating lease due 3 to 5 years	3,693,000	'	'	'	'
Operating lease obligation due more than 5 years	704,000	'	'	'	'
Loss Contingencies [Line Items]	'	'	'	'	'
Insurance Reserves	6,111,000	'	'	'	'
Insurance Reserve Current	805,000	'	'	'	'
Probable loss	'	'	'	4,383,000	12,758,000
Number of executives	2	2	'	'	'
Number of shareholders	2	2	'	'	'
Number of lawsuits	6	6	'	'	'
Number of lawsuits filed in Court of Chancery	2	2	'	'	'
Number of lawsuits filed in Court of Common Pleas	4	4	'	'	'
Number of customers	'	'	12	'	'
Number of states	'	'	10	'	'
Number of days to submit response	'90 days	'90 days	'	'	'
Damages sought	$42,050,000	145,000,000	'	'	'

Employee_Stock_Benefit_Plans_D

Employee Stock Benefit Plans (Details) (USD $)

6 Months Ended

3 Months Ended

6 Months Ended

1 Months Ended

0 Months Ended

In Thousands, except Share data, unless otherwise specified

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Feb. 28, 2013

12-May-14

12-May-14

12-May-14

Jun. 30, 2014

Jul. 31, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jul. 31, 2014

Jun. 30, 2014

Jun. 30, 2014

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Non-Employee Director Stock Option Plan [Member]

Non-Employee Director Stock Option Plan [Member]

Non-Employee Director Stock Option Plan [Member]

Non-Employee Director Stock Option Plan [Member]

2005 Equity Plan [Member]

2005 Equity Plan [Member]

2005 Equity Plan [Member]

2005 Equity Plan [Member]

Employees And Consultants [Member]

Executive Employees [Member]

LCA [Member]

LCA [Member]

Subsequent Event [Member]

Common Stock [Member]

Stock Options [Member]

Subsequent Event [Member]

Common Stock [Member]

Stock Options [Member]

Employees And Consultants [Member]

Employees And Consultants [Member]

Executive

Employee Stock Benefit Plan [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock authorized in stock option plan (in shares)

'

'

'

'

'

'

'

'

120,000

370,000

'

'

3,000,000

6,000,000

'

'

Common stock issued or reserved for issuance (in shares)

'

'

'

'

'

'

'

'

'

'

7,000

14,578

'

'

867,432

1,293,601

Number of Options [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding (in shares)

'

'

'

1,132,678

'

'

'

'

'

'

'

'

'

'

'

'

Granted (in shares)

'

'

'

180,500

71,500

109,000

'

'

'

'

'

'

'

'

'

'

Exercised (in shares)

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

Cancelled (in shares)

'

'

'

-4,999

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding (in shares)

'

'

1,308,179

1,308,179

'

'

'

'

'

'

'

'

'

'

'

'

Options exercisable (in shares)

'

'

517,179

517,179

'

'

'

'

'

'

'

'

'

'

'

'

Weighted Average Exercise Price [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding (in dollars per share)

'

'

'

$16.51

'

'

'

'

'

'

'

'

'

'

'

'

Granted (in dollars per share)

'

'

'

$14.11

$14.80

$13.70

'

'

'

'

'

'

'

'

'

'

Exercised (in dollars per share)

'

'

'

$0

'

'

'

'

'

'

'

'

'

'

'

'

Cancelled (in dollars per share)

'

'

'

$58.63

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding (in dollars per share)

'

'

$16.02

$16.02

'

'

'

'

'

'

'

'

'

'

'

'

Options exercisable (in dollars per share)

'

'

$16.45

$16.45

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation cost related to non-vested option grants and stock awards

$9,693

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted-average period over which unrecognized compensation is expected to be recognized

'2 years 9 months 18 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average assumptions to estimate fair value of grants of stock options [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Risk-free interest rate (in hundredths)

'

'

2.21%

2.17%

'

'

'

'

'

'

'

'

'

'

'

'

Volatility (in hundredths)

'

'

76.61%

78.41%

'

'

'

'

'

'

'

'

'

'

'

'

Expected dividend yield (in hundredths)

'

'

0.00%

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

Expected life

'

'

'5 years 6 months

'5 years 6 months

'

'

'

'

'

'

'

'

'

'

'

'

Estimated forfeiture rate (in hundredths)

'

'

0.00%

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares issued to non-employee director (in shares)

5,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate fair value of shares issued to non-employee director

75

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options granted to purchase common stock (in shares)

'

'

'

180,500

71,500

109,000

'

'

'

'

'

'

'

'

'

'

Strike price of options granted (in dollars per share)

'

'

'

$14.11

$14.80

$13.70

'

'

'

'

'

'

'

'

'

'

Vesting period of options granted

'

'

'

'

'5 years

'4 years

'3 years

'

'

'

'

'

'

'

'

'

Expiration period of options granted

'

'

'

'

'10 years

'10 years

'

'

'

'

'

'

'

'

'

'

Number of executive employees

'

'

'

'

'

'

'

3

'

'

'

'

'

'

'

'

Aggregate fair value of options granted

'

'

'

'

718

975

'

'

'

'

'

'

'

'

'

'

Total stock based compensation expense

$2,556

$2,584

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restricted stock units granted (in shares)

'

'

'

'

'

'

141,337

'

'

'

'

'

'

'

'

'

Price of restricted stock (in dollars per share)

'

'

'

'

'

'

$0.01

'

'

'

'

'

'

'

'

'

Business_Segments_and_Geograph2

Business Segments and Geographic Data (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
			Segment
Business Segments and Geographic Data [Abstract]	'	'	'	'
Number of operating units	'	'	4	'
Results of operations from business segments [Abstract]	'	'	'	'
Revenues	$52,120	$58,065	$102,195	$115,281
Costs of revenues	17,652	11,390	27,997	23,256
Gross profit	34,468	46,675	74,198	92,025
Gross profit % (in hundredths)	66.10%	80.40%	72.60%	79.80%
Allocated operating expenses [Abstract]	'	'	'	'
Engineering and product development	723	814	1,518	1,587
Selling and marketing expenses	30,420	30,468	62,046	59,794
Unallocated operating expenses	11,452	6,268	19,039	11,927
Total operating expenses	42,595	37,550	82,603	73,308
Operating (loss) profit	-8,127	9,125	-8,405	18,717
Interest and other financing income, net	-175	-134	-321	-3
(Loss) Income before income tax benefit (expense)	-8,302	8,991	-8,726	18,714
Operating Segments [Member] | Consumer [Member]	'	'	'	'
Results of operations from business segments [Abstract]	'	'	'	'
Revenues	28,453	48,673	69,323	97,733
Costs of revenues	3,983	7,174	10,233	14,691
Gross profit	24,470	41,499	59,090	83,042
Gross profit % (in hundredths)	86.00%	85.30%	85.20%	85.00%
Allocated operating expenses [Abstract]	'	'	'	'
Engineering and product development	305	279	592	497
Selling and marketing expenses	23,223	26,703	50,381	52,334
Unallocated operating expenses	0	0	0	0
Total operating expenses	23,528	26,982	50,973	52,831
Operating (loss) profit	942	14,517	8,117	30,211
Interest and other financing income, net	0	0	0	0
(Loss) Income before income tax benefit (expense)	942	14,517	8,117	30,211
Operating Segments [Member] | Physician Recurring [Member]	'	'	'	'
Results of operations from business segments [Abstract]	'	'	'	'
Revenues	8,607	7,376	15,826	13,331
Costs of revenues	3,425	3,014	6,255	5,945
Gross profit	5,182	4,362	9,571	7,386
Gross profit % (in hundredths)	60.20%	59.10%	60.50%	55.40%
Allocated operating expenses [Abstract]	'	'	'	'
Engineering and product development	257	317	567	641
Selling and marketing expenses	4,268	3,233	8,279	6,407
Unallocated operating expenses	0	0	0	0
Total operating expenses	4,525	3,550	8,846	7,048
Operating (loss) profit	657	812	725	338
Interest and other financing income, net	0	0	0	0
(Loss) Income before income tax benefit (expense)	657	812	725	338
Operating Segments [Member] | Professional [Member]	'	'	'	'
Results of operations from business segments [Abstract]	'	'	'	'
Revenues	1,917	2,016	3,903	4,217
Costs of revenues	1,361	1,202	2,626	2,620
Gross profit	556	814	1,277	1,597
Gross profit % (in hundredths)	29.00%	40.40%	32.70%	37.90%
Allocated operating expenses [Abstract]	'	'	'	'
Engineering and product development	161	218	359	449
Selling and marketing expenses	274	532	731	1,053
Unallocated operating expenses	0	0	0	0
Total operating expenses	435	750	1,090	1,502
Operating (loss) profit	121	64	187	95
Interest and other financing income, net	0	0	0	0
(Loss) Income before income tax benefit (expense)	121	64	187	95
Operating Segments [Member] | Clinics [Member]	'	'	'	'
Results of operations from business segments [Abstract]	'	'	'	'
Revenues	13,143	0	13,143	0
Costs of revenues	8,883	0	8,883	0
Gross profit	4,260	0	4,260	0
Gross profit % (in hundredths)	32.40%	'	32.40%	'
Allocated operating expenses [Abstract]	'	'	'	'
Engineering and product development	0	0	0	0
Selling and marketing expenses	2,655	0	2,655	0
Unallocated operating expenses	0	0	0	0
Total operating expenses	2,655	0	2,655	0
Operating (loss) profit	1,605	0	1,605	0
Interest and other financing income, net	0	0	0	0
(Loss) Income before income tax benefit (expense)	$1,605	$0	$1,605	$0

Business_Segment_and_Geographi

Business Segment and Geographic Data, Revenue by Geographical Data (Details) (USD $)	3 Months Ended				6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014		Jun. 30, 2013		Jun. 30, 2014		Jun. 30, 2013		Dec. 31, 2013
Net revenues by geographic area [Abstract]	'		'		'		'		'
Revenues	$52,120		$58,065		$102,195		$115,281		'
Reportable Geographical Components [Member]	'		'		'		'		'
Net revenues by geographic area [Abstract]	'		'		'		'		'
Revenues	52,120		58,065		102,195		115,281		'
Long-lived assets by geographic area [Abstract]	'		'		'		'		'
Long-lived assets	29,138		'		29,138		'		10,489
Reportable Geographical Components [Member] | North America [Member]	'		'		'		'		'
Net revenues by geographic area [Abstract]	'		'		'		'		'
Revenues	41,803	[1]	42,033	[1]	81,776	[1]	86,932	[1]	'
Long-lived assets by geographic area [Abstract]	'		'		'		'		'
Long-lived assets	27,859		'		27,859		'		9,119
Reportable Geographical Components [Member] | Asia Pacific [Member]	'		'		'		'		'
Net revenues by geographic area [Abstract]	'		'		'		'		'
Revenues	2,638	[2]	9,440	[2]	5,014	[2]	15,202	[2]	'
Long-lived assets by geographic area [Abstract]	'		'		'		'		'
Long-lived assets	4		'		4		'		0
Reportable Geographical Components [Member] | Europe (Including Israel) [Member]	'		'		'		'		'
Net revenues by geographic area [Abstract]	'		'		'		'		'
Revenues	7,084		5,861		14,492		11,494		'
Long-lived assets by geographic area [Abstract]	'		'		'		'		'
Long-lived assets	1,270		'		1,270		'		1,370
Reportable Geographical Components [Member] | South America [Member]	'		'		'		'		'
Net revenues by geographic area [Abstract]	'		'		'		'		'
Revenues	595		731		912		1,653		'
Long-lived assets by geographic area [Abstract]	'		'		'		'		'
Long-lived assets	5		'		5		'		0
Reportable Geographical Components [Member] | United States [Member]	'		'		'		'		'
Net revenues by geographic area [Abstract]	'		'		'		'		'
Revenues	38,612		37,329		73,379		75,336		'
Reportable Geographical Components [Member] | Canada [Member]	'		'		'		'		'
Net revenues by geographic area [Abstract]	'		'		'		'		'
Revenues	3,191		4,704		8,397		11,596		'
Reportable Geographical Components [Member] | Japan [Member]	'		'		'		'		'
Net revenues by geographic area [Abstract]	'		'		'		'		'
Revenues	$290		$7,452		$988		$11,715		'
[1]	United States $38,612 $37,329 $73,379 $75,336 Canada $3,191 $4,704 $8,397 $11,596
[2]	Japan $290 $7,452 $988 $11,715

Significant_Customer_Concentra2

Significant Customer Concentration (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
	Customer	Customer	Customer	Customer
Revenue, Major Customer [Line Items]	'	'	'	'
Number of major customers	0	2	0	2
Customer A [Member]	'	'	'	'
Revenue, Major Customer [Line Items]	'	'	'	'
Percentage of revenue generated by single major customer (in hundredths)	'	11.00%	'	11.00%
Customer B [Member]	'	'	'	'
Revenue, Major Customer [Line Items]	'	'	'	'
Percentage of revenue generated by single major customer (in hundredths)	'	12.00%	'	9.00%